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ABSTRACT
Injection drug use along with the opioid epidemic have contributed to many problems
facing communities locally and nationally. Preventative and harm reduction measures are
important for individual and public health due to the adverse outcomes of injection drug use such
as increased transmission of hepatitis B, hepatitis C, and human immunodeficiency virus, as well
as increased rates of opioid overdose (CDC, 2019; Strain, 2021). One preventative approach,
syringe exchange programs (SEPs), have been shown to reduce the amount of contaminated
needles and rate of infections while increasing access to additional resources and likelihood to
attend a treatment program (Hagan et al., 2000; Hurley et al., 1997; Tookes et al., 2012).
Clinic 555 currently operates a SEP in Saint Paul, Minnesota and expressed a need to
acquire funding for the development of a mobile syringe exchange program (J. Saavedra,
personal communication, January 19, 2022). This project served to aid Clinic 555 to acquire
funding by assisting with writing sections A1, A2, and B of the grant application for the
Department of Health and Human Services Substance Abuse and Mental Health Services
Administration (SAMHSA) Fiscal Year 2022 Harm Reduction Program Grant. Researchers
compiled a literature review to demonstrate the need for and advantages of SEPs, describe the
benefits of mobile health clinics, and display the demographics of the target population. The goal
of this community service project to aid in the contribution of the grant writing process was
successful as Clinic 555 incorporated the completed sections into the final grant proposal. Clinic
555 was notified in June 2022 that they were not selected as recipients for the SAMHSA grant (J.
Saavedra, personal communication, June 1, 2022). Clinic 555 did express their intentions to
further utilize the contributions from this project for future grant applications.
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Chapter 1: Introduction
Introduction
Drug use is an area of interest for public health campaigns and preventative medicine.
Drug use and addiction physiology is a disease state that often requires extensive management
and treatment by medical professionals along with accessible social support systems. In
conjunction with addiction, illicit drug use poses a public health concern due to the associated
blood borne pathogens that are transmitted with sharing contaminated needles (Carlson, 2021;
Hagan et al., 1995). Pathogens transmitted with contaminated needles and injection drug use
include human immunodeficiency virus (HIV), hepatitis B, and hepatitis C (CDC, 2019). Further
medical concerns that injection drug users (IDUs) encounter include thrombophlebitis,
endocarditis, and cellulitis (Cleveland Clinic, 2019a; Cleveland Clinic, 2019b; Sexton & Chu,
2019). Taking preventative measures and providing appropriate services to IDUs not only helps
on an individual level but plays an important role for improved public health.
One public health service that targets IDUs are syringe exchange programs (SEPs).
Syringe exchange programs function as a place for IDUs to safely dispose of contaminated
needles and syringes in exchange for sterile ones (Ramsey County, 2021). Syringe exchange
programs provide a myriad of other services like wound care and sexual health services (Ramsey
County, 2021). SEPs reduce rates of transmission of pathogens like HIV and the hepatitis
diseases as well as improve rates of sobriety and access to medical care for IDUs (Hagan et al.,
2000; Hurley et al., 1997; Strathdee et al., 1999). Despite their successes, SEPs remain limited in
several aspects such as fixed structure sites and the inability to directly access underserved
communities. Mobile Health Clinics (MHCs), defined as mobile structures (often a vehicle), are
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staffed by medical professionals and offer various medical services. Mobile health clinics have
been shown to increase access to underserved and uninsured individuals (Bennet et al., 2020).
The development of a mobile syringe exchange program (MSEP) is a proposed solution and
agent to further propagate the benefits provided by SEPs. The purpose of this community service
project is to assist a local clinic to apply for funding for the future roll out of a MSEP to expand
their reach and services to the community. Chapter One provides a background to this subject,
the project’s purpose and possible limitations, and the impact to the Physician Assistant (PA)
profession and health care system.
Background
Prescription opioids are considered appropriate treatment for selective patients with
severe chronic pain that is unresponsive to other treatments or for post-operative pain
management (Webster, 2017). Opioids have a serious risk for misuse due to their addictive
nature. Patient risk factors for opioid misuse include substance use disorder, family history of
substance use disorder, mental health disorders, history of legal problems or incarceration, white
race, and age less than 40-45 years old (Becker & Starrels, 2021). According to the 2016-2017
National Survey on Drug Use and Health in the United States, among the approximately 76
million adults in the United States who were prescribed opioid drugs in the prior year, 12%
reported opioid misuse. Of that 12%, higher rates of other substance use including cannabis,
heroin, and benzodiazepines as well as higher rates of depression were reported (Becker &
Starrels, 2021).
Heroin is an illicit opioid made from morphine that can be administered in a number of
ways. The most common forms of consumption of heroin are smoking, snorting, and injecting
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the drug (Hardey et al., 2021). Prescription opioids and heroin are pharmacologically similar as
they both work on the opioid receptors in the body and produce similar analgesic and euphoric
effects (Compton et al., 2016). According to a study done by Muhuri, Gfroerer, and Davies
(2013), the incidence of heroin use was 19 times higher among people who reported prior
prescription opioid misuse than the incidence among those who reported no previous prescription
opioid misuse. In a systematic review done by Compton et al. (2016), it was reported that misuse
of prescription opioids was associated with transitioning to heroin use. In the same systematic
review, it was reported that the patterns of prescription opioid use suggest that patients start with
oral misuse and then switch to more efficient and more potent forms of drug administration such
as insufflation, smoking or injection as tolerance develops (Compton et al., 2016).
Common localized infections among IDUs are cellulitis and thrombophlebitis (Cleveland
Clinic, 2019a; Cleveland Clinic, 2019b). Cellulitis is a skin infection and thrombophlebitis is
blood clot formation and inflammation involving the superficial veins that can become infected
(Cleveland Clinic, 2019a; Cleveland Clinic, 2019b). Common systemic blood borne infections
due to injection drug use include human immunodeficiency virus (HIV), hepatitis B and C virus,
and infective endocarditis ( Carlson, 2021; Hagan et al., 1995; Sexton & Chu, 2019). Hepatitis C
is the most common chronic viral liver infection in the United States and infective endocarditis is
an infection involving the valves of the heart (Kim, 2019; Sexton & Chu, 2019).
Human immunodeficiency virus is acquired from blood or body fluids including vaginal
fluid, semen/sperm, and breast milk of an infected person (Carlson, 2021). Injection drug users
who are sharing unclean needles are at a higher risk for acquisition of HIV. Other high risk
populations include men who have sex with men, people with multiple sex partners, people who
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exchange sex for drugs, and people who have had sexual contact with a person who is HIV
positive or a person at risk for HIV infection. Human immunodeficiency virus may have a
latency period of several years before any symptoms appear in which people may not know they
have the infection and can still spread it. Human immunodeficiency virus is a very expensive
diagnosis potentially costing a patient over $300,000 in their lifetime. Pre-exposure prophylaxis
(PrEP) is an oral medication that is taken once daily to prevent HIV infection. Pre-exposure
prophylaxis can reduce the risk of HIV from sexual transmission by more than 90% and from
injection drug use by more than 70%. A post exposure prophylaxis (PEP) pill is also available.
This can be taken within 72 hrs of a possible HIV exposure and is prescribed for 28 days
(Carlson, 2021).
According to the Center for Disease Control (CDC) HIV Basic Statistics webpage for the
year 2019, an estimated 1,189,700 people had HIV at the end of 2019 in the United States
(Center for Disease Control [CDC], 2021f). According to the Minnesota Department of Health
(MDH) HIV Incidence Report, 59 of the 226 new cases reported in Minnesota in 2020 were in
the city of Minneapolis, specifically concentrated in Hennepin and Ramsey County (2021a).
With HIV still being a prevalent issue in the United States and in Minnesota, risk reduction
strategies for transmission should be explored and expanded upon. One such strategy that will be
discussed is the implementation and expansion of syringe exchange programs (SEPs).
The appearance of SEPs in the United States began in the 1980s in response to the rising
rates of HIV infection in communities with high injection drug use prevalence (CDC, 2019).
Since then, SEPs have expanded services to further aid in the reduction of blood borne
pathogens, infections, and sexually transmitted diseases (STDs). When SEPs first began, funding
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was scarce and many operated illegally (Hurley et al., 1997). Until 2009, there was a
congressional ban that prohibited use of federal funds for SEPs. However, as increasing numbers
of SEP successes have been reported, more support and acceptance for these programs has been
seen (Hurley et al., 1997).
Syringe exchange programs have been found to lower seroprevalence of HIV. The CDC
conducted a study from 1988 to 1993 that showed a 11% decrease in HIV annual seroprevalence
in cities with SEPs (Hurley et al., 1997). New Haven, Connecticut documented a 24% drop in
HIV seroprevalence after the city implemented an SEP (Pollack et al., 2002). In addition to HIV,
IDUs that visit SEPs have shown a lower likelihood for individuals to contract hepatitis B and
hepatitis C (Hagan et al., 1995). Cities with SEPs also have significantly less contaminated
needles found along streets (Tookes et al., 2012).
Syringe exchange programs have been effective in helping IDUs get connected to drug
abuse and addiction treatment programs. Seattle’s SEP reported their clients being five times
more likely to undergo treatment programs than IDUs that did not use their SEP (Hagan et al.,
2000). IDUs who use SEPs have shown more likelihood to maintain their sobriety (Hagan et al.,
2000; Strathdee et al., 1999). Because of these successes, 97% of SEPs now offer referral to
these drug abuse and addiction treatment programs (Hagan et al., 2000).
Ramsey County Public Health opened Clinic 555, a SEP in St. Paul, Minnesota, in July
of 2018 (Collins, 2018). The mission of the SEP is to reduce rates of HIV and other infections
commonly associated with injection drug use as well as reducing the rising overdose death rate
occurring in Ramsey County (Ramsey County, 2021). Clinic 555 is positioned to primarily serve
a specific population in Ramsey County including the vulnerable, underserved, and IDUs.
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Injection drug users usually do not have access to traditional medical care because of lack of
insurance coverage, lack of transportation, or financial difficulties (Matsuzaki et al., 2018). To
help reach this population, Clinic 555’s services are confidential and anonymous to their
clientele. The SEP component runs free of charge to clientele and other services offered by
Clinic 555 have a sliding fee scale to help make them affordable (Ramsey County, 2021). A
future goal of Clinic 555 is to expand their program to include a mobile health clinic (MHC) to
increase community access.
Mobile health clinics (MHCs) are defined as a vehicle that is often run and staffed by
medical professionals including physicians, nurses, and public health workers among others
(Bennet et al., 2020). The services MHCs offer vary significantly and depend on the
organizational and affiliation goals of the individual clinic but can include primary care, mental
health, and preventive health services. The value of MHCs lie in their ability to physically access
previously underserved communities, provide specific treatment, as well as gain significant
community support and trust. They provide the unique ability to link community and public
health services with clinic settings and advanced providers (Bennet et al., 2020). Due to their
intrinsically mobile and flexible characteristics, MHCs have the unique ability to access
previously underserved communities as well as contribute to significant cost reductions in the
healthcare system.
Mobile Health Map is a program that tracks and monitors the functioning, availability,
and services of MHCs within the United States. Currently, approximately 2,000 MHCs are
operating within the United States (Bennet et al., 2020). Mobile health clinics can be found
within each of the 50 states with many of them located in areas of increased population density
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and larger cities. While MHC services can cover a broad-spectrum including mammography,
pediatric health, disaster relief, and vision care, approximately 47% of MHCs reported functions
with services solely for preventative care. This was followed by 41% reporting services focused
on primary care and another 28% listing dental care as their primary services (Bennet et al.,
2020).
Modeling demonstrated that approximately 5.2-7 million visits are made to MHCs
annually (Bennet et al., 2020). Of those MHCs involved in the modeling, it was noted that
approximately 41% of clients who utilized MHC services were uninsured and accounted for
approximately 2.1 million visits to MHCs yearly. The percentage of patients accessing MHCs
under MediCaid services was approximately 30% and patients covered by Medicare was 15%.
Bennet et al. (2020) reported that MHCs provided care to a larger percentage of people of color
compared to the general U.S. population. While 13.4% of the general population identified as
African American according to the 2010 U.S. Census, the average percentage of clients
identifying as African American utilizing MHCs was 35%. While only 18.3% of the 2010 U.S.
census respondents identified as Latino or Hispanic, data in this study found that the average
percentage of clients utilizing MHCs who identified as Hispanic or Latino was 26.6% (Bennet et
al., 2020).
Problem Statement
Opioid use and the transmission of pathogens via contaminated needles and syringes is a
public health concern throughout the United States. Syringe Exchange Programs (SEPs) have
been proven effective in combating several of the associated problems with injection drug use
including reduced rates of transmission of human immunodeficiency virus (HIV), hepatitis B and
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C as well as contributing to sobriety for many SEP clientele (Hagan et al., 2000; Tookes et al.,
2012). Despite the effectiveness of SEPs nationally, one common barrier that continues to face
injection drug users (IDUs) is access to SEPs, including lack of transportation or financial
concerns (Yu et al., 2017). A practical solution to this problem would be the expansion of SEPs
into mobile units. Mobile health clinics (MHCs) have had significant success in reaching
previously underserved and inaccessible communities (Bennet et al., 2020). In order for the roll
out and expansion of SEPs into mobile units, more funding is needed for establishment as well as
structural support and planning. This paper attempts to analyze the effectiveness of SEPs as well
as discussing the benefits associated with mobile SEPs (MSEPs).
Purpose
The purpose of this project is to aid Clinic 555 in obtaining funding to expand their SEP
along with other services to a mobile health clinic. Services that Clinic 555 currently offer in
addition to the SEP include, but are not limited to, HIV testing, HIV prevention including PrEP
and PEP distribution, STD screening, contraception, and wound care (Ramsey County, 2021).
The proposal for funding entails a review of current and previous literature on successes of
MHCs as well as SEPs to show the importance of implementing such a program. Therefore, the
researchers will gather and discuss relevant evidence and literature to assist Clinic 555 in their
grant proposal for a potential mobile syringe exchange program (MSEP).
Significance of the Problem
The effects of the opioid epidemic are far reaching. From 2005 to 2014, opioid related
hospitalizations rose over 64% amounting to 225 per 100,000 people in the United States
(Lynden & Binswanger, 2019). According to the CDC, over 70% of overdose deaths in 2019
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were opioid related, including both intravenous heroin use and misuse of prescription or illicitly
manufactured opioids (CDC, 2021b). According to the CDC, the increased prescribing of opioids
for pain relief has contributed to one of the biggest opioid overdose epidemics in the United
States. While the opioid epidemic initially began due to the increase in availability and overuse
of prescription pain relief, it has evolved into a widespread endemic involving synthetically
produced opioids and a resurgence of heroin use (Janetto, 2021). In a 2016 survey conducted by
the National Survey on Drug Use and Health, 11.8 million Americans over the age of 12 reported
non-medical (misuse) of opioids. In 2016, 42,000 Americans died from opioid related drug
overdoses, up 27% from 2015 (Lyden & Binswanger, 2019). This current public health crisis
involves high mortality rates, an increased need for emergency services, opioid addiction
therapy, and treatment options (Janetto, 2021).
Despite measures taken to regulate the use of opioids, medical providers such as Medical
Doctors (MDs), Nurse Practitioners (NPs), and Physician Assistants (PAs) are faced with the
harsh reality of the dangers of prescribing opioids to patients, and ultimately may play a part in
their patients' addiction or misuse of the medication. According to CDC guidelines, medical
providers must review Prescription Drug Monitoring Programs prior to any new opioid
prescription, whether it is for short or long term use (Lyden & Binswanger, 2019). This
prescribing practice standard is a safeguard against multiple opioid prescriptions being written to
the same person by different providers across the country. Medical providers may be involved in
treating patients with opioid dependence or addiction. Treatment options include therapy and
medications, which reduce the cravings or effects of withdrawal from opioids (Lyden &
Binswanger, 2019). To effectively treat IDUs, providers must be aware and educated on the signs
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of opioid abuse, take preventative measures not to over prescribe this class of drugs, be
knowledgeable on current treatment options, and be familiar with community resources like
Clinic 555 for referrals for IDUs.
Limitations of the Study
Limitations for the project entail limited grant writing and application experience among
researchers. The completion and success of any grant portions and application will be reliant on
communication between researchers and Clinic 555 as well as aid from associated faculty with
grant writing experience. Further limitations include advanced projected timelines and
scheduling constraints for researchers for the completed project in accordance with grant
application deadlines.
Definition of Terms
Analgesics: A class of drugs which have a pain relieving effect (Cleveland Clinic, 2021).
Benzodiazepines: A class of central nervous system depressant drugs used to treat anxiety and
insomnia (Cleveland Clinic, 2019c).
Bloodborne pathogens: Infection that occurs in the blood commonly associated with
needlesticks, needle sharing, and any contact with contaminated blood. Common pathogens
include HIV, HBV, and HCV (“Bloodborne Pathogens and Needlestick Prevention”, n.d.)
Cellulitis: A non-contagious bacterial infection of the skin and other body tissues (Cleveland
Clinic, 2019b).
Census Block: A parcel of land that is surrounded by streets or other defining landmarks such as
railroads or bodies of water on all four sides (Tookes et al., 2012).
HBV: Hepatitis B Virus, a virus which causes a serious liver infection (CDC, 2021e).
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HCV: Hepatitis C Virus, a virus which causes a serious liver infection. The infection can be
either acute or chronic and has a wide range of symptoms (CDC, 2020b).
HIV: Human Immunodeficiency Virus, a virus which can be transmitted through sharing needles,
unprotected sex, and contact with contaminated bodily fluids (CDC, 2021d).
Hypoxia: An insufficient amount of oxygen in body tissues to keep up with demand (Bhutta et
al., 2021)
Infective Endocarditis: A non-contagious infection of the heart valves or inner lining caused by
bacteria or fungi (CDC, 2004).
Intravenous drug users: Individuals who use drugs such as heroin, cocaine, prescription opioids,
and methamphetamine by injecting the drug into their veins (Bell, 2019).
Mobile health clinic: A vehicle that is often run and staffed by medical professionals including
physicians, nurses, and public health workers among others and offers a variety of services
(Bennet et al., 2020).
Naloxone: Also known as “Narcan”, is an opioid antagonist that reverses the effects of
opioids/opioid overdose (“Understanding naloxone”, 2020)
Opioid: A class of drugs which work on the opioid receptors in the nerve cells, this type of drug
has a pain relieving effect and also gives a sense of euphoria (Cleveland Clinic, 2019c).
Overdose: A toxic amount of a drug or combination of drugs which overwhelms the body
causing injury or poison (“Understanding naloxone”, 2020; Cleveland Clinic, 2019c).
PrEP: A preventative medication for individuals who are at high risk for contracting HIV via
injection drug use or sex. It is effective at preventing contraction of the HIV virus (CDC, 2021c).
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Syringe exchange program: A community based program which provides clean needles and
syringes, along with resources for addiction counseling, the screening and treatment of HIV and
hepatitis, and other health related services which vary program to program (CDC, 2019)
Seroprevalence: Found by using seroprevalence surveys which are investigations using serology
tests, also known as antibody tests, to determine the rate of infection of various pathogens in a
population of individuals, in a geographical location, or time frame (CDC, 2020a).
Thrombophlebitis: A blood clot of the vein characterized by swelling, pain and redness
(Cleveland Clinic, 2019a).
Conclusion
Both SEPs and MHCs play an important role in healthcare, with SEPs particularly
influencing preventive care and management of illicit/illegal drug use and associated disease
pathogens. Expanding currently existing SEPs into mobile syringe exchange programs (MSEPs)
could potentially augment the services and benefits provided from programs. Clinic 555 located
in St. Paul, MN has demonstrated the need to develop a MSEP to increase access of their
services to the underserved, IDU clientele, and the broader community (Ramsey County, 2021).
In order to financially support a MSEP for Clinic 555, acquiring funding through grant
applications is paramount. The goal of this project is to assist Clinic 555 with grant writing and
to secure funding for a MSEP initiation. The following section will provide a relevant literature
review discussing the overview of opioid and injection drug use, associated pathogens and
disease states, SEP development, services and benefits, historical funding avenues, and MHC
developments and services.
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Chapter 2: Literature Review
Introduction
Injection drug use and blood borne pathogens are a significant and widespread public
health concern nationally. Syringe exchange programs provide a variety of services with
emphasis on providing a place for injection drug users (IDUs) to safely and correctly dispose of
contaminated needles and syringes in exchange for sterile ones (Ramsey County, 2021). A
discussion of the pathophysiology of drug use, addiction, and common blood borne pathogens as
well as services commonly offered by syringe exchange programs (SEPs), their success,
outcomes, and funding sources will be detailed below. Further, description of mobile health
clinics (MHCs), which additionally offer an alternative method to aid in reaching certain
communities and bridging several financial and physical barriers to healthcare will be discussed.
Opioid Use Disorder and Addiction
Opioids are natural or synthetic substances that act on the opioid receptors on nerve cells
(Strain, 2021). They have the ability to elicit analgesic and central nervous system depressant
effects and can cause euphoria. Opioids bind to and stimulate transmembrane neurotransmitter
G-coupled protein receptors mu, kappa, and delta. The G-proteins then begin intracellular signal
transduction that leads to a systemic effect such as reward, withdrawal, or analgesia. There are
mu receptors in the central nervous system that, when acted on by opioids, result in respiratory
depression, analgesia, euphoria (from increased dopamine release), and miosis (Strain, 2021).
Opioids can be prescribed by a licensed medical provider for pain relief and are
considered a controlled substance because of their potential for abuse and addiction. According
to the CDC, methadone, oxycodone, and hydrocodone are the most common prescription opioids
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involved in overdose deaths (CDC, 2017). Fentanyl is a legal synthetic opioid used in medicine
for severe pain such as cancer pain (CDC, 2021a). Fentanyl related overdoses and deaths are
connected to illegally made fentanyl in the United States (CDC, 2021a). The most commonly
abused opioid by injection is the illegal drug heroin, which may be laced or cut by other opioids
such as fentanyl and methadone (Strain, 2021). Risk factors for opioid use or dependence include
a prior history of substance use disorder, younger age, severe pain, and mental health disorders.
Childhood maltreatment is also a risk for opioid use disorder (Strain, 2021).
Patients that present to healthcare facilities with opioid use disorder are more likely to be
impoverished and engage in illegal activity to get money to supply their addiction (Strain, 2021).
These patients may have lost their jobs and relationships due to their drug use. Some patients
may not show any signs or symptoms of drug abuse as they have developed tolerances (Strain,
2021).
Complications of Injection Drug Use and Addiction
Complications from injection drug use and addiction include both localized and systemic
infections, withdrawal, overdose, and increased mortality (Strain, 2021). Localized infections
may include cellulitis and infection of the injection site such as thrombophlebitis. Common
systemic infections that occur as complications of injection and IV drug use are human
immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B (HBV), and right sided
infective endocarditis. Human immunodeficiency virus is a blood borne pathogen that can be
spread due to high risk behaviors that injection drug users (IDUs) may engage in including
sharing of unclean needles, prostitution, unprotected sex, or sex with a high risk population such
as IDUs (Pieper & Treisman, 2021). Hepatitis C virus is another blood borne pathogen that can
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be spread through needle sharing in IDUs. It is the most common chronic liver infection in the
United States (Kim, 2019). Infective endocarditis is an infection of the heart valves, most
commonly caused by S. aureus (Sexton & Chu, 2019). The largest risk factor for right sided
infective endocarditis is injection/IV drug use. 90% of patients with right sided infective
endocarditis are people who inject drugs. As heroin use in the United States increased between
the years 2006-2013, the incidence of right sided infective endocarditis also increased from 6-8%
of hospitalizations between the years 2000-2008 to 12% in the year 2013 (Sexton & Chu, 2019).
Overdose is a serious complication of opioid drug use and abuse. According to a review
published by the National Drug and Alcohol Research Center, the “typical” heroin death tended
to involve users in their 20s and 30s who were experienced IDUs and were also using
coingestants such as alcohol and benzodiazepines (Stolbach & Hoffman, 2020). The classic signs
of opioid toxicity include depressed mental status, decreased respiratory rate (<12 rpm),
decreased tidal volume, decreased bowel sounds, and miotic/constricted pupils. Seizures can
result from hypoxia from any opioid but are normally associated with tapentadol, tramadol, or
meperidine. Bystander naloxone intervention can help to resuscitate opioid overdose patients and
reduce mortality (Stolbach & Hoffman, 2020).
HIV/AIDS and Opioid Drug Overdose Statistics in Minnesota
Minnesota’s Department of Health tracks rates of HIV/AIDS and opioid drug overdoses
to keep record of public health trends within the state. According to the Minnesota Department
of Health HIV/AIDS statistics page for the year 2020, 226 HIV cases were reported in Minnesota
(MDH, 2021a). This was decreased compared to 2019 and was below the five year average from
2016-2020 (MDH, 2021a). Data from the Minnesota Department of Health Opioids Drug
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Overdose Dashboard showed that opioid involved overdose deaths have increased in Minnesota
since the year 2000 (MDH, 2021b). Specifically, in 2019, there were 427 opioid related deaths
and synthetic opioids were involved in the greatest proportion of these deaths. Although the
number of opioid prescriptions dispensed has continued to decrease since 2015, from 2019 to
2020, emergency room visits for opioid overdoses substantially increased for all opioid
categories excluding heroin, which remained stable. It was also found that patients between the
ages of 15-34 had the greatest number of emergency room (ER) visits for opioid overdoses in
2020, and males had more ER visits in 2020 for opioid overdoses than females. The same data
set shows that only 1 in 10 people with a substance abuse disorder receive treatment in the
United States (MDH, 2021b).
HIV/AIDS and opioid drug overdose is a significant public health risk and concern both
nationally and within the state of Minnesota. Strategies to decrease risk factors for infectious
diseases and overdoses in IDUs are essential. One of these public health measures that aims for
reducing these risk factors is known as a syringe exchange program (SEP). In the following
section, the efficacy and implementation of SEPs will be discussed.
Overview of Syringe Exchange Programs
Syringe exchange programs are community services that began appearing in the United
States around the 1980s. While individual programs may differ in the amount and type of
services provided, SEPs often center around the pertinent need for injection drug users (IDUs) to
properly dispose of their contaminated needles and subsequently receive sterile ones (CDC,
2019). The first cities to open syringe exchange programs were Boston, Massachusetts, Tacoma,
Washington, and San Francisco, California (Tookes et al., 2012).
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Some SEPs are affiliated with local state government sectors and Department of Health
agencies, while others are non-profit, privately run programs (Hurley et al., 2012). In the 1990s,
many SEPs were small, operated illegally, and had unreliable financial support. This was
primarily due to a congressional ban that prohibited the use of federal funds to establish or help
in the maintenance of SEPs. This ban was lifted in 2009 by the Obama administration and SEPs
have subsequently grown in number since then (Hurley et al., 1997). Syringe exchange programs
in the United States have expanded to approximately 388 SEPs in 2021 (SSP Locations, 2021).
In addition to the geographic and numeric expansion of SEPs, the services provided by SEPs
have continued to diversify as well. Services have expanded to include pregnancy and women’s
health care, STD screening, wound and infection care, as well as connection to drug abuse or
addiction treatment programs (Grau et al., 2002; Hagan et al., 2000; Moore et al., 2012;
Robinowitz et al., 2014).
The primary goal of some of the original SEPs was to reduce the prevalence of certain
infections in a community, such as HIV, hepatitis B, and hepatitis C commonly associated with
sharing needles (Tookes et al., 2012). Syringe exchange programs adhere to the theory that the
complex biobehavioral nature of addiction must be accepted in order to successfully reduce rates
of needle transmissible infections (O’Hara, 2016). To reduce the rate of infections, SEPs have
been employing harm reduction tactics. The goal of harm reduction aims to reduce high risk
behaviors that can lead to infections, such as needle sharing, without trying to completely cut out
the original causative behavior of injection drug use.
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Oppositions Against SEPs
The formation, funding, and functioning of SEPs have not been universally accepted and
have been the source of community disagreement since their onset. Some of the primary
objections and concerns noted within several studies regarding public and political opinions of
SEPs include the potential for increasing the number of needles disposed of improperly,
increased crime, and increased IDUs due to availability of material (Doherty et al., 2000;
Guydish et al., 2002; Hurley et al., 1997; Tookes et al., 2012). Studies have been conducted to
analyze potential negative effects and assess the validity of such concerns toward SEPs. A
common practice in many SEPs is the one-to-one method, which gives out one clean
one-time-use syringe in exchange for a used syringe (Hurley et al., 1997). One peer-reviewed
study conducted a visual inspection of city streets comparing San Francisco, a city with SEPs, to
Miami, a city without any (Tookes et al., 2012). For every 1000 census blocks, a city block being
a parcel of land that is surrounded by streets, 371 syringes were found in Miami and only 44
syringes in San Francisco. In Miami, 95% of syringes were reported to be disposed of
improperly, which was 82% higher than in San Francisco. A study in Boston had similar results
in finding the number of syringes discarded had decreased by nearly half after the establishment
of the SEP (Doherty et al., 2000).
Studies conducted in Baltimore and New York City investigated whether the
establishment of SEPs increased crime and violence in neighborhoods where they were located.
Baltimore compared crime reports in areas that did and did not have a SEP (Marx et al., 2000).
Researchers specifically compared crime rates associated with drug possession, police resistance,
and violence. No differences in crime rates were found between the neighborhoods that had SEPs
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established and those that did not. The analysis in New York City went further and analyzed all
crime reported in relation with distance to the nearest SEP (Galea et al., 2001). Researchers
investigated if there was a geographic correlation with increased crime reporting closer to the
locations of SEPs. No association of increased violence or significant changes in crime rates
were found in residential areas closer to a SEP.
One of the additional political influences that prevented Congress from lifting the ban on
the allowance of federal funding for SEPs and led to controversy surrounding SEPs was the
notion that SEPs would encourage and increase injection drug use (Hurley et al., 1997). Several
studies have indicated that SEPs do not cause an increase in injection drug use, but in fact help
increase the amount of IDUs admitted to treatment programs for drug abuse and addiction
(Guydish et al., 1993; Hagan et al., 2000; Strathdee et al., 1999). In Seattle, over 75% of IDUs
reported reducing the number of injections they were receiving since the start of the SEP (Hagan
et al., 2000). Clients of Seattle’s syringe exchange program were five times more likely to
undergo drug and addiction treatment programs than injection drug users that did not use a SEP.
The clients that did undergo drug and addiction treatment were more likely not to relapse than
IDUs that did not utilize the SEP. Additionally, IDUs who utilized an SEP in Baltimore were
three times more likely to enroll in a treatment program than IDUs who did not use the SEPs
(Strathdee et al., 1999). Fifteen percent of IDUs who used SEPs in Baltimore reported being in a
detoxification program while also undergoing a methadone maintenance program to aid in
quitting injection drug use. Since SEPs have been shown to effectively connect IDUs with
services to reduce their drug use and obtain sobriety, approximately 97% of all SEPs now
administer drug treatment referrals to their clients (Hagan et al., 2000).
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Syringe Exchange Program Benefits and Successes
Syringe exchange programs have played a significant role in the reduction of HIV
prevalence for over the past 30 years. The CDC analyzed 81 cities, some with SEPs and some
without, for annual changes in the incidence of HIV from 1988 to 1993 (Hurley et al., 1997). It
was found that annual seroprevalence of HIV was 11% lower in cities that had at least one SEP.
Another example of SEP effectiveness was noted by a study conducted in New Haven,
Connecticut (Pollack et al., 2002). This city had approximately 1,900-2,600 IDUs and a high rate
of poverty, homelessness, drug abuse, and HIV/AIDS. The SEP in New Haven was reported as a
36 foot MHC that provided services to four locations. The SEP tested for HIV on the used
syringes before and after the SEP was established. HIV rates dropped 24% after the introduction
of the SEP.
Wodak and Cooney (2006) performed an international review summarizing the findings
of seven studies. These seven studies were conducted with the support of US government
agencies and include observational studies, ecological studies, and prospective cohort studies.
These studies were conducted between 1991 to 2001. All seven studies showed a similar result of
a reduction in HIV seroprevalence with the use of SEPs. The analysis indicated that all seven
prior reviews found that SEPs prevented HIV transmission while not increasing injection drug
use. The authors rated the seven studies according to the Bradford Hill Criteria for sound
scientific method. It was determined that all the studies that showed HIV reduction had a good
strength of association, replication of findings, temporal sequence, biological plausibility,
coherence of evidence, reasoning by analogy, cost effectiveness, absence of negative
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consequences, feasibility of implementation, expansion and coverage, unanticipated benefits, and
application to special populations (Wodak & Cooney, 2006).
In addition to contributing to the reduction of HIV transmission rates, SEPs have been
found to prevent and reduce incidences of hepatitis B and C. Researchers found that IDUs who
did not attend or use the services of an SEP located in Tacoma, Washington were six times more
likely to contract hepatitis B and seven times more likely to contract hepatitis C (Hagan et al.,
1995). In addition, since HIV is a disease transmissible both from contaminated needles and
sexual contact, drug use and sexual health is commonly addressed together in SEPs (O’Hara,
2016). One SEP in Baltimore expanded their services to include reproductive health (Moore et
al., 2012). This program targeted exotic dancers who use SEPs in the “red light district”, a
population that is typically underserved in the medical community. Fifty seven percent of the
dancers reported recent use of injection drugs and 43% reported recently exchanging sexual acts
for money. Both are high risk behaviors for the spread of HIV, hepatitis B, and hepatitis C. The
program already included syringe exchange services for the neighborhood before the addition of
reproductive health. Seventy five percent of the SEP clients reported not having reproductive
health care before this change. The program reported high success rates, receiving over 220 visits
in the first 21 months for contraceptive administration, STD, HIV, and pregnancy testing (Moore
et al., 2012).
As mentioned in previous sections, other common infections that can be transmitted via
use of contaminated syringes and improper injection technique are skin infections and wound
abscesses. One SEP established in Oakland, California started incorporating wound and abscess
care to their program in 1997 (Grau et al., 2002). Over 20 two-hour sessions, the wound clinic
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treated 173 visits. After the initial roll-out of the program, the SEP continued to see a steady
average of 170 patients per month. A SEP located in Baltimore also incorporated a mobile
wound care unit to their services in 2012 (Robinowitz et al., 2014). Over the first 16 months,
they received 1,872 visits with 116 chronic wound treatments and 52 for acute wound or abscess
treatments.
One reason SEPs have been increasing in prevalence over the past several decades is
because of the financial benefits to the individual as well as the community. On the individual
level, if a patient contracts HIV the cost to the patient is between $253,000 and $402,000 over
their lifetime (Farnham et al., 2013). On a community level, financial burden relief can be to
local fixtures such as hospitals and government (Farnham et al., 2013; Pollack et al., 2002;
Ronan et al., 2014). For example, once a cellulitis infection in an IDU reaches the point where a
hospital visit is required, the cost can end up being extremely high for the hospitals. There were
approximately half a million hospitalizations for 2012 in the U.S. related to only opioid abuse. A
major portion of these hospitalizations serviced IDUs and cost the medical system 14.8 billion
dollars for these visits from IDUs, primarily via Medicaid (Ronan & Herzig, 2016). The
introduction of the SEP located in New Haven contributed to a 20% decline in visits to the
emergency department for their clients (Pollack et al., 2002). Costs to run an SEP can be as low
as $5 per patient per visit, as reported for the SEP in Oakland, which would save the state and
federal government money in the long term (Grau et al., 2002).
Funding for Syringe Exchange Programs
Limited funding has been reported as one of the most common problems facing SEPs
(Beletsky et al., 2012). Historically, federal funding has played a limited role in the funding of
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SEPs resulting from the complication of political agendas and ideologies. A prohibition enacted
in 1988 as part of the Public Health and Welfare Act banned the use of federal funding for SEPs
(Fisher, 2012). Proponents of the ban have argued that federal funding for SEPs would act as a
governmental “stamp of approval” of illegal drug use and could propagate subsequent negative
messaging around such use. This includes concerns that the support of SEPs could serve as a
contraindication against direct measures local law enforcement and public health agencies have
taken towards reducing drug use. In contrast, opponents of the federal ban have argued that SEPs
play a significant and important role in the reduction of blood-borne infectious diseases as well
as providing access to various public health services. Additional statements in favor of federally
funded SEPs argue that the presence and support offered by SEPs as well as associated treatment
programs have the potential to reduce rates of drug use (Fisher, 2012).
Some of the first significant changes to legislation came during 2009 with the
Consolidated Appropriation Act, which modified the ban and enabled the allocation of funding
to support SEPs (Beletsky et al., 2012). Later in 2016, further approval of federal funds for SEPs
was included with the omnibus spending package during the Obama administration (Wolitski,
2016). A 2016 release by Dr. Richard Wolitski of the Department of Human and Health Services
details specific guidance and requirements that must be met not only to apply and receive federal
funding for SEPs but also in the use of the funds themselves. Requirements for federal funding
application include that the applying health department consult with the CDC and demonstrate
that their served population is either directly experiencing or at high risk of experiencing
significant increases in hepatitis and HIV infections associated with injection drug use. Once the
CDC has approved the request by confirming and providing evidence of this risk, the health
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departments may proceed with their application with the corresponding federal agency (Wolitski,
2016).
In additional requirements that must be met by the SEP per Wolitski and the HHS
guidelines, the applicator must include specific guidelines around program structure and service
requirements (2016). Some examples of these requirements include that the programs must
adhere to federal, state, and local laws, coordinate with local law enforcement agencies, offer
comprehensive services such as HIV and hepatitis testing, referral to substance abuse treatment
programs, mental health services, and sexual health services. Once funding is approved, the HHS
also includes restrictions and guidelines on how the funds may be used and distributed. This
includes mandates that the funds themselves cannot be used to purchase syringes or needles
directly but may instead be available for other expenses often associated with the functioning of
SEPs such as staffing, naloxone, educational and outreach materials, and testing kits for hepatitis
C and HIV (Wolitski, 2016).
Prior to the changes in federal legislation allocating federal funding for SEPs, a 2004
study released the results of annual surveys conducted of known SEPs in the US by staff of the
Beth Israel Medical Center in New York City and of the North American Syringe Exchange
Network (NASEN) (Des Jalaris et al., 2004). These results showed state and local funding along
with foundation grants and private donations were the majority source of funding for SEPs. In
addition, the funding allocated by the state and local government for those SEPs who were
recipients accounted for approximately 87% of total spending. These results demonstrate the
reliance of SEPs on state and local funding and show that in the instance where this funding is no
longer available or is revoked, SEPs would unlikely be able to maintain the same level and
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availability of services. It was noted that of those SEPs who did receive federal funding, a clear
correlation between clinic size and amount of funding received was established. Approximately
85% of surveyed respondents reported that there was a clear correlation between the size of the
SEPs, determined by the number of syringes exchanged, and the use of federal funds.
Specifically, it was noted that the larger the size of the SEP, the more likely the program would
be the recipient of federal funds.
Despite the change in legislation allowing for federal funding that came after 2006, many
SEPs continued to face challenges accessing these funds. Most SEPs continued to operate
primarily using local and state government funds, with some assistance from private donations
and grants (Beletsky et al., 2012). A peer-reviewed study of cross-sectional surveys of all
currently operating SEPs in the United States from October 2010 to March 2011 found that
following the change to the Consolidated Appropriation Act, 79% of SEP funding continued to
come from state and local governments with the remainder from private sources. Of the SEPs
surveyed, only three programs (1.6%) reported the use of federal funding via the Substance
Abuse and Mental Health Services Administration and CDC mechanisms. Programs that
received federal funding did not use the monies to expand services but instead used them as
supportive funds such as funding staffing and equipment procurement. In contrast to expected
outcomes, survey responses from the SEPs suggested that despite the change in legislation, many
SEPs believed it would have little to no impact on both the everyday functioning and services of
the programs nor offering any financial support (Beletsky et al., 2012).
While many of the SEP respondents intended to pursue federal funding, the majority of
respondents indicated they were expecting to face significant barriers (Beletsky et al., 2012). Of
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the barriers anticipated, one of the most commonly noted was the assumption that despite the
changes in legislation, federal funding would still be significantly limited and inaccessible as a
result of increased competition for funds. Other respondents noted that another barrier likely to
prevent them from pursuing and receiving federal funding would be the reduction of local
funding resulting from a crowd-out effect wherein local funding would be reduced or no longer
applicable should the programs receive federal funding. Since the majority of funding for many
programs came from local funding, receiving federal funding would not have a cost-effective
outcome. Further barriers included the concern over certain legal barriers that are listed as
requirements for application of funding (such as statements of support from local law agencies
and specific legal status requirements of the programs themselves), which seemed unlikely,
unattainable, and cost ineffective for the programs. Additional barriers to accessing federal
funding were found in the lack of educational or guiding materials for programs to apply for
funding, as well as limited resources of monitoring and compliance requirements for application,
especially for programs of smaller size. Finally, and perhaps one of the most significant barriers
facing the appropriation of federal monies would be the potential requirements and restrictions
that would be tied to such funding. Some of these requirements and guidelines could include
implementation of access to counseling, additional health services, and vaccination programs
that would impede the manner and functioning of the already established programs. Syringe
exchange program respondents that were most likely to anticipate funding barriers discussed
above were those that lacked fixed structural sites (such as mobile or delivery SEPs) and those
that lacked any Department of Health affiliation or necessary legal status (Beletsky et al., 2012).
Despite significant legislative changes allocating federal funding for SEPs, significant barriers
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continued to face many programs. Access to federal and local funding is one of the biggest
challenges in the expansion and mobilization of SEPs.
Mobile Services and Gap Bridging to the Underserved
The introduction of a mobile health clinic (MHC) to a vulnerable population is proven to
be particularly impactful in the treatment of communicable diseases, preventative health, and
access to care (Yu et al., 2018). Of the estimated 2,000 MHCs currently being operated in the
United States, there is a variety of services offered including: primary care, dental,
ophthalmology, and mental health screenings. As services each MHC provides can vary so
significantly, an analysis of MHCs within the U.S. found that the average annual cost of the
clinic was highly dependent on services provided. Overall average cost of services annually per
MHC was $632,369 (Bennet et al., 2020). However, dental clinics averaged an annual total cost
of $1,169,559 and primary clinics averaged $981,092. Preventive clinics in contrast, averaged
$319,868. Evidence suggested MHCs offer a return on investment (ROI) for the state. In Texas, a
mobile pediatric asthma unit proved a ROI as high as 45% within the first two years of operation
(Orsak et al., 2018).
Patients who use MHCs nationwide have reported barriers to traditional healthcare
options such as lack of transportation, insurance status, financial limitations, cultural/linguistic
barriers, hours of operation, lack of providers, and intimidation of traditional healthcare settings
(Matsuzaki et al., 2018; Yu et al., 2018). Similar results were found from a survey administered
to IDUs and hazardous drinkers (Matsuzaki et al., 2018). Lack of insurance, other financial
burdens, inability to physically access care, and limited social support contributed to their lack of
access to care. Further results indicated that IDUs and hazardous drinkers had experienced more
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discrimination and poor treatment at clinics compared to their non using counterparts. In fact,
patients visiting the mobile SEP in Baltimore reported they were likely to return to the SEP for
continued care but would not attend a clinic appointment even after being referred (Moore et al.,
2012).
The clientele that SEPs serve are composed largely of unemployed individuals, homeless
individuals, IDUs, and people living in poverty. For example, 70% of clients who visited a
mobile SEP in Baltimore were unemployed, 35% were IDUs, 27% had a history of sex work,
and 26% had been recently incarcerated (Pollack et al., 2002). When used in conjunction with
SEPs, MHCs can reach underserved populations effectively and affordably (Matsuzaki et al.,
2018). Another study in Baltimore showed MHCs were able to have more clients to test for HIV
and reached a higher risk population (Yu et al., 2018). Transportation is a common barrier that
mobile units help to address, as stated above, especially in underserved neighborhoods. The
syringe exchange program in Oakland, California, reported that 84.8% of patients live within ten
miles of the clinic (Grau et al., 2002). Montreal, Canada did not have mobile units, but showed
this dependence on distance by using needle drop boxes to receive dirty needles. The use of the
drop boxes dropped by almost half the farther clients had to walk to use the boxes (de Montigny
et al., 2010). This data suggested that mobile SEPs can offer a myriad of services at an affordable
rate, reach multiple underserved communities, and provide effective intervention, prevention,
and care.
Conclusion
Syringe exchange programs have consistently been found to reduce the rates of diseases
commonly transmitted via IV drug use as well as providing a variety of supportive services to the
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community. Additionally, mobile health clinics have had significant success rates in reaching and
serving communities otherwise underserved. This project will focus on aiding Clinic 555, a SEP
located in Ramsey County, Minnesota, with the creation of a proposal grant to implement a
mobile unit providing syringe exchange and sexual health services to Minneapolis and St. Paul.
In the following section, the methods of this project will be discussed.
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Chapter 3: Methodology
Introduction
The purpose of Chapter three is to discuss the methodology of this project, which aims at
assisting Clinic 555 with the acquisition of funding for a MHC. This will be pursued via an
application for The Department of Health and Human Services Substance Abuse and Mental
Health Services Administration Fiscal Year 2022 Harm Reduction Program Grant. The primary
goal of this project was to gather comprehensive literature review data and materials regarding
IDUs, SEPs, and MHCs to help with the compilation of information needed for the grant
submission. This grant (if awarded) will help address Clinic 555’s need for funding, allow for
them to expand the reach of their current services by the implementation of a MHC, and increase
accessibility to a SEP for IDUs, with the aim to ultimately implement harm reduction and
decrease the rates of transmission of common blood borne pathogens (Hagan et al., 2000; Tookes
et al., 2012). Chapter three will cover the background of Clinic 555, the population it serves, the
needs of their organization, a description of the grant, the grant writing process, and projected
outcomes if the grant is awarded.
Needs Assessment
Clinic 555 was opened in July of 2018 by Saint Paul Ramsey County Public Health’s
office (see Appendix D). It is the only fixed syringe exchange program located in St. Paul,
Minnesota and offers syringe exchange services five days a week. The services include one to
one contaminated syringe for sterile syringe exchange, HIV testing, HCV testing, STD testing,
wound care, naloxone kit distribution, vaccinations, substance abuse treatment program referrals,
social services, and overdose prevention education. Its location is strategic to underserved
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populations and IDUs of St. Paul who are disproportionately impacted by poverty, racial and
ethnic disparities, and communities impacted by individuals with substance use disorder and
homelessness. The mission of Clinic 555s SEP is to reduce rates of transmission of blood borne
pathogens, reduce overdose deaths, and offer non-judgemental harm reduction services to the
clientele. Since opening, the SEP has seen a 387% increase in number of encounters, and 555%
increase in sterile syringe distribution (see Appendix D).
The populations this organization primarily serves are IDUs, minorities, and low income
individuals. For example, 371 HIV tests were administered in 2020, and of those tests 63% were
given to racially diverse individuals (see Appendix D). Staff at Clinic 555 reported the
demographics of the population as very diverse and clients who require services can utilize them
at will during operating hours (J. Saavedra, personal communication, January 19, 2022). The
services provided are utilized by IDUs who commonly do not have access to traditional medical
care because of lack of insurance coverage, lack of transportation, or financial difficulties
(Matsuzaki et al., 2018). To effectively target this population, Clinic 555’s services are offered as
confidential and anonymous to all of their clientele. The staff at Clinic 555 shared with the
researchers that a future goal of Clinic 555s fixed SEP is to expand their program to include a
MHC to increase their impact radius and reach members of the greater community that otherwise
do not have access to the clinics services . One way nonprofit organizations such as Clinic 555
acquire funding is by writing and submitting a detailed grant proposal to the federal or state
government as they become available, for example, Clinic 555 has been funded by the Title X
grant for over 50 years (J. Saavedra, personal communication, January 19, 2022 Appendix D). In
the past, Clinic 555 has partnered with students of medical programs such as Bethel University's
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Physician Assistant program, for similar projects. Due to understaffing, underfunding, and time
constraints, Clinic 555 required the assistance of the researchers to acquire federal grant funding
for the MHC project. A sizable federal grant could help fund a fully outfitted MHC which will
not only provide clean syringes, but also do HIV testing, vaccinations, STD testing and mental
health counseling for underserved communities in Ramsey County, Minnesota (J. Saavedra,
personal communication, January 19, 2022).
Project Plan and Implementation
The Department of Health and Human Services Substance Abuse and Mental Health
Services Administration Fiscal Year 2022 Harm Reduction Program Grant (HRG) is available to
offer financial support to community establishments, which implement harm reduction services,
including SEPs and overdose prevention programs (see Appendix B). The primary goal for this
grant is to provide funding for organizations that offer harm reduction services. Some suggested
examples demonstrated in the grant Notice Of Funding Opportunity are slowing the spread of
blood borne pathogens, increased awareness and access to STD prevention and testing, and the
provision of addiction treatment options to high risk individuals such as overdose prevention
counseling, clean syringes, and naloxone. The target populations of the program are individuals
residing in rural communities, LGBTQ+ personnel, and minorities. There are no known ethical
implications of working with this population via this grant proposal at this time. The HRG details
grant recipients must focus efforts on meeting people just as they are to implement harm
reduction services (see Appendix B).
This grant award is up to $400,000 dollars per year for a total of up to three years, for a
maximum allotment of 1.2 million US dollars. The estimated number of awards is 25, with an
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anticipated total funding of 29,250,000 over three years (see Appendix B). As detailed in the
grant, the spending and allocation of awards is limited to specific categories defined by the
Substance Abuse and Mental Health Services Administration (SAMHSA) including : the hiring
of staff to train in harm reduction behavior treatments, mobile outreaches, necessary supplies,
harm reduction stigma campaigns, innovative approaches to harm reduction, and public
education of the Good Samaritan laws regarding harm reduction. The HRG details the
expectation that recipients must implement projects within four months of receiving the funding,
and the project must incorporate the aforementioned services in areas of a known gap or need.
Recipients of the grant must provide evidence-based services to the population of focus by
submitting required quarterly reports while adhering to local, state and federal laws with their
services provided (see Appendix B).
Organizations that are eligible for the HRG grant include non-profits, independent school
districts, tribal organizations, state governments/territories, and county governments (see
Appendix B). All of the required applicant materials were submitted by Clinic 555 by the
deadline of February 7th, 2022. The staff at Clinic 555 and the researchers collaborated two
weeks before the application due date and decided the Project Narrative section was where the
researchers research and resources would be of best use. This was divided based on the literature
collected on the effectiveness of SEPs and MHCs the researchers had completed, and the other
sections which the staff previously completed that were most relevant to their organization (see
Appendix B H. Zander, personal communication, January 20, 2022).
The HRG Project Narrative section was composed of five sections, A-E, and was within
the requirement of no more than 10 pages (see Appendix B). Section A was composed of two
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parts, Part 1: population of focus and statement of need and Part 2: why the population needs
harm reduction services and how the organization plans to meet those needs. Section B was an
optional section, which offered 10 bonus points for organizations who could prove they provide
services to priority populations. Section C proposed implementation and approach was composed
of three subsections: C-1 describe the goals and measurable objectives of the proposed grant, C-2
describe how the organization will implement the harm reduction service delivery, and C-3
provide a table of the three year timeline of the proposed project. The next section, Section D
was also composed of three subsections: D-1 include organization history, mission, annual
operating budget, number of staff, and all services offered. The second subsection D-2 required
the history of the organization's ability to implement harm reduction services. Section D-3
required a list of all staff and their positions, including relevant staff to the proposed project. The
last section was Section E: data collection and performance measurement. This section required
the applicants to provide information on how the organization will acquire the required data to
remain part of the grant program (see Appendix B). The researchers completed sections: A Part 1
& 2, and Section B bonus points for providing services to priority populations. Clinic 555
completed section C-E and implemented the majority of the work the researchers completed into
the final submission (see Appendix D)
In composing Section A, researchers utilized data from the US Census Bureau to describe
the population demographic breakdown of St. Paul, MN residents, which encompassed the target
population (see Appendix D). For Section A1, the researchers included the percentage of
individuals who identify as LGBTQ+, provided data on dialects spoken, education levels,
average income levels, income level disparities between Whites and Blacks, and homeownership
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statistics in St. Paul. The researchers provided recent statistics of homelessness describing racial
disparities of homelessness, overdose risk, and opioid death risk disparities between White,
Black, and Native Americans. Leading into Section A2, the researchers demonstrated the need
for harm reduction services and detailed how the organization would rise to meet that need. The
need was represented with data from the Minnesota Department of Health, which demonstrated
the rising rates of opioid overdose deaths and blood borne pathogen infections in Minnesota (see
Appendix D) . The researchers also detailed common obstacles IDUs face in receiving medical
treatment or utilizing SEPs such as lack of finances, insurance, transportation, or mistrust in
doctors (Matsuzaki et al., 2018). It was proposed that more effective harm reduction strategies be
implemented via the mobilization of the current SEP at Clinic 555. The effectiveness of SEPs in
harm reduction was discussed, as well as the effectiveness of similar MHCs being run in other
states (see Appendix D).
Section B of the HRG application offered 10 extra points to applicants who can prove
they serve more than 50% racial minorities, LGBTQ+, or rural communities (see Appendix B).
Clinic 555 currently serves 55% white Americans (H. Zander, personal communication, January
20, 2022). Due to the unique flexibility of the proposed MHC, Clinic 555 could target the
priority populations and travel directly to underserved minorities via the MHC, which the
researchers demonstrated by providing data of neighboring census tracts. The researchers utilized
a population density map of St. Paul from the Department of Planning and Economic
Development (2021), which showed the increase in racial diversity in neighboring census tracts
relative to Clinic 555. Census Tract 336, which is within a short drive of Clinic 555, represents
71.4% Black, 18.1% Asian, 1.9% Hispanic, and 4.9% White.
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Limitations
The limitation of this project was that the researchers had limited grant writing
experience. This was addressed by working with the staff at Clinic 555, who had many years of
experience writing grant proposals, they oversaw the final product, and submitted what was most
crucial to their application.
Conclusion
Clinic 555 has a rich history and offers many harm reduction services to IDUs and
underserved communities of Ramsey County, Minnesota. The researchers utilized their research
in Chapter one and Chapter two to write Sections A Part 1 & 2 and Section B of the HRG grant.
The staff at Clinic 555 utilized the research as they saw fit and implemented it in their final grant
submission. In Chapter four, the researchers will discuss the results of the project.
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Chapter 4
Introduction
Syringe exchange programs (SEPs) function as a preventative health measure to aid
injection drug users (IDUs) with proper disposal of contaminated needles as well as provide
access to additional resources (CDC, 2019). While SEPs have been shown to provide significant
public health benefits to the community, a fixed structural site can be problematic for clientele
who may be unable or less likely to physically access the location due to transportation barriers
or preconceived notions about health care clinics (Matsuzaki et al., 2018; Yu et al., 2018). Clinic
555, which is partially funded and operated in conjunction with Ramsey County Department of
Health, currently operates a fixed location SEP in St. Paul, Minnesota (Ramsey County, 2021).
Per Clinic 555 staff, the implementation of a mobile syringe exchange program (MSEP) is the
goal of Clinic 555 to better access and serve the community of Ramsey County (J. Saavedra,
personal communication, January 19, 2022). The goal of this project was to aid Clinic 555 in
their implementation of a future MSEP by assisting in the grant writing process, specifically
contributing to Clinic 555’s application to the the Department of Health and Human Services
Substance Abuse and Mental Health Services Administration (SAMHSA) Fiscal Year 2022
Harm Reduction Program Grant. The following chapter will summarize the results of this
project, detail limitations encountered in the completion of this project as well as further goals of
the project.
Summary of Results
Associated complications with injection drug use include opioid misuse and overdose and
the transmission of bloodborne pathogens (Strain, 2021). Syringe exchange programs have been
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proven to reduce HIV, HBV, and HCV transmission and to catalyze SEP clientele sobriety
(Tookes et al., 2012; Hagan et al., 2000). Lack of access to SEPs due to financial or
transportation limitations is a common barrier amongst IDUs (Yu et al., 2017). The expansion of
SEPs into mobile units is a solution to improved access as MHCs have shown successes in
reaching underserved populations (Bennet et al., 2020). Funding is the primary need for the roll
out of MSEPs and this project attempts to address that need by assisting in the grant writing
process for Clinic 555.
The mission of Clinic 555 is to reduce both the rates of HIV and opioid overdose deaths
in IDUs located in Ramsey County through their SEP (Ramsey County, 2021). In 2020, out of
the 226 new cases of HIV reported in Minnesota, 59 were in the city of Minneapolis, specifically
concentrated in Hennepin and Ramsey Counties (MDH, 2021a). Opioid involved overdose
deaths have continually increased in Minnesota since the year 2000 (MDH, 2021b). Clinic 555
offers services in addition to the SEP such as HIV testing, HIV prevention including PrEP and
PEP, STD screening, contraception, and wound care (Ramsey County, 2021). In 2021,
researchers communicated with Clinic 555 staff member Jessie Saavedra who stated that
mobilization of the SEP has been a longstanding goal. Mr. Saavedra proposed that expanding the
reach of the SEP to the greater Ramsey County area and the city of St. Paul would increase
clientele and further decrease the number of IDUs impacted by infectious diseases and or
overdose in Minnesota. Clinic 555 expressed the initial need for the implementation of a MSEP
as the acquisition of funding (J. Saavedra, personal communication, January 19, 2022).
The researchers assisted in writing sections A1, A2, and B of the project narrative portion
of the SAMHSA grant application. Section A1 detailed the population of focus and statement of
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need (see Appendix B). Section A2 focused on why the population has a need for harm reduction
services and how the organization plans to meet those needs through their project. Section B
would award bonus points for organizations which provide services to priority populations
including racial minorities, LGBTQ+ members, or rural communities (see Appendix B).
Once the researchers of this project completed writing the grant sections A1, A2, and B,
the draft was sent to Clinic 555 staff Hilary Zander and Jessie Saavedra. Clinic 555 determined
how much of the researchers’ contribution was incorporated in the final grant application to be
submitted. The researchers’ draft of sections A1, A2, and B consisted of a combination of
sources found through the literature review in Chapter 2 and additional supporting sources. The
new sources utilized were primarily to aid in the demographic information of St. Paul, Minnesota
where Clinic 555 operates, which falls outside the realm of the literature review.
The literature review data was specifically helpful when defending the successes of SEPs
in harm reduction for IDUs. Of the 33 references cited in Clinic 555’s final submission of the
grant, 27 were contributed by the researchers; of those 27, 15 were from the literature review
portion. The information in section A2 was compiled from the literature review which assisted in
detailing the need for harm reduction in IDUs and how a MSEP would be able to better reach
IDUs.
Clinic 555 staff utilized 96% of the section A1 and 88% of the section A2 drafts. There
were minor grammatical edits and some ancillary language was removed. The structure and flow
of the draft was kept the same in the final document. An example of a minor edit would be a
sentence in the draft written “The population of St. Paul as of April 1st, 2020 was 311,527
people, equating to 5,484.3 people per square mile” and the final submission was “According to
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the 2020 U.S. Census, the population of St. Paul is estimated at 311,527 people, equating to
5,484 people per square mile” (see Appendices B and C).
The final section the authors wrote for Clinic 555 was section B. The final grant
document did not include the researchers’ contributions from section B. Clinic 555 staff utilized
internal data from their organization rather than national data, which researchers utilized to make
their argument for a majority of the population being a minority. None of researchers’ draft of
section B was utilized in the final grant section B; however, the content was instead incorporated
in Attachment 10 of the final grant (see Appendix E). Attachment 10 further detailed the
population of focus for Clinic 555’s proposed mobilized services (see Appendix E).
Approximately 65% of Attachment 10 consisted of writing from the researchers draft of section
B. This outcome was an unexpected addition to the planned methodology.
Feedback from Clinic 555 reported that contributions from the researchers were helpful.
According to Ms. Zander, who was responsible for writing and submitting the final grant
proposal, the grant draft from the researchers was “definitely an asset!” (H. Zander, personal
communication, February 10, 2022). Unfortunately, on June 1st, 2022, Mr. Saavedra informed
the researchers that Clinic 555 did not meet expectations of the organization and subsequently
did not receive the SAMHSA grant. Mr. Saavedra continued on to state that Clinic 555 will
continue to apply for grants to help fund the goal of expansion with a MSEP (see Appendix F).
Limitations
While communicating with the staff at Clinic 555 about their needs for grant writing, the
researchers initially thought they would be working on a grant application due later in the year
2022. The opportunity to assist with the SAMHSA grant came unexpectedly which put time
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constraints for writing grant portions A1, A2 and B. The researchers had two weeks to review
their research and complete the sections on time. All communications with the staff at Clinic 555
were online through email and Zoom meetings. Although there may have been some benefit to
the researchers to visit the site and meet with staff in person, due to COVID-19 restrictions, the
researchers were unable to go to Clinic 555. One of the submitted sections, Section B, of the
grant was not utilized in the intended section; the staff at Clinic 555 submitted their own data and
research for it.
Further Projects
If this project were to be replicated for a similar goal and outcome, gathering the most
current relevant research would be necessary. A contribution and addition which would have
been helpful in the researchers grant writing process would have been to acquire more data and
statistics directly from Clinic 555 to incorporate into the grant. Utilizing additional local data and
internal studies would have made the sections stronger (See Appendix B). Sections A1 and A2,
along with Chapters 1 and 2, may be utilized by the staff at Clinic 555 for future grants; however,
it will not be confirmed until the next grant opportunity arises (H. Zander, personal
communication, April 27, 2022).
Considering the successes of MHCs in other specialties and areas of the country, the
research completed for this project could be utilized for other MHC grant proposal projects.
Medically underserved populations involve a variety of clientele, and additional MHCs offering
services different than a SEP could reach new populations of individuals seeking care. This
might involve MHC in specialties such as dental, ophthalmology, pulmonology, sexual health
services, and wound clinics.

48
Conclusion
Injection drug use poses a challenge to public health secondary to the risks users face
such as increased incidence and risk of several disease states including HIV, HBV, HCV, and
addiction (CDC, 2019). Injection drug use also negatively impacts the greater community and
surrounding areas via increased hospitalizations and healthcare associated costs for acute
overdose and fatalities, as well as increased opioid dependency and addiction (Ronan & Herzig,
2016). The opioid epidemic and public health implications is prevalent within Ramsey County,
Minnesota where this project was implemented. Opioid related overdoses and deaths in 2020
increased by 196% in the area compared to 2010, despite the number of prescriptions dispensed
decreasing over the same time period (MDH, 2020a). This data demonstrates a heightened public
need for increased access to services and preventative measures. Clinic 555 in Saint Paul,
Minnesota currently offers several preventative services to the community including a SEP and
reproductive health services (Ramsey County, 2021). Several studies have shown the efficacy of
SEPs in reducing injection drug use, achieving and maintaining sobriety of clientele, decreasing
amounts of contaminated needles, and decreased HIV seroprevalence in communities (Tookes et
al., 2012; Hurley et al., 1997; Hagan et al., 2000). Mobile health clinics have also been
demonstrated to offer additional preventative measures of previously inaccessible services due to
their flexible nature. Mobile health clinics often serve clientele who are more racially and
ethnically diverse, medically underserved and uninsured, and who otherwise may not have
access to care (Matsuzaki et al., 2018; Yu et al., 2018).
A proposed solution to combat the public health concern and rising opioid use due to
injection drug use within the Ramsey County area is the development and initiation of a MSEP.
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It is the goal of Clinic 555 to expand their current SEP services into a mobile sector in order to
better serve and reach the surrounding area of Saint Paul, Minnesota. In order for the expansion
into a MSEP, Clinic 555 expressed the need to attain funding (J. Saavedra, personal
communication, January 19, 2022). While funding for SEPs historically have primarily come
from private donors and local governments, one federal funding opportunity eligible to Clinic
555 is the SAMHSA grant (Des Jalaris et al., 2004; J. Saavedra, personal communication,
January 19, 2022). The goal of this project was to aid Clinic 555 in their application for the
SAMHSA grant. Awardees of the SAMHSA grant receive $400,000/yearly for a total of three
years to fund services primarily focused in harm reduction (see Appendix B). Recipients of the
SAMHSA grant were notified in June 2022 (see Appendix B). Clinic 555 reported to researchers
that they did not receive the grant but were encouraged moving forward in the attempt to receive
further grants (J. Saavedra, personal communication, June 1, 2022).
Researchers at Bethel University utilized data obtained from a multitude of sources to
complete sections A1, A2, and B of the project narrative portion of the SAMHSA grant which
detailed population demographics of the grant as well as describing and detailing the need for
services in the selected area and population (see Appendix B). Information obtained from the
Saint Paul Department of Planning and Economic Development was utilized to demonstrate the
potential that the services offered via this funding would reach communities representing greater
than 50% ethnically and racially diverse communities (St. Paul Department of Planning and
Economic Development, 2021). The complete and finalized SAMHSA grant application was
submitted on February 7th, 2022 in combination with Bethel University Physician Assistant
Students and Clinic 555 Staff.

50
This project has contributed to the education and professional development of the
researchers. While several limitations faced the researchers, such as lack of limited experience in
grant writing, the outcome of this project ultimately aided in educational development as well as
advancing the institutional relationships between Clinic 555 and Bethel University’s Physician
Assistant Program. It is the hope of this project that the contributions to the SAMHSA grant will
lead to the acquisition of funds for continued harm reduction services. The goal researchers have
in the completion of this project is that data and information collected and summarized can be
further utilized for future grant applications and research both within the St. Paul metro area and
across the nation.
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APPENDIX B
NOFO Harm Reduction Grant Application Information and Requirements

Department of Health and Human Services
Substance Abuse and Mental Health Services
Administration
FY 2022 Harm Reduction Program Grant
(Short Title: Harm Reduction)
(Initial Announcement)

Notice of Funding Opportunity (NOFO) No. SP-22-001
Assistance Listing Number No.: 93.243

Key Dates:
Application Deadline

Applications are due by February 7, 2022.

Intergovernmental
Review (E.O. 12372)

Applicants must comply with E.O. 12372 if their state(s)
participate(s). Review process recommendations from
the State Single Point of Contact (SPOC) are due no
later than 60 days after application deadline.

Public Health
System Impact
Statement
(PHSIS)/Single State
Agency Coordination

Applicants must send the PHSIS to appropriate state
and local health agencies by the administrative
deadline. Comments from the Single State Agency are
due no later than 60 days after the application deadline.
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EXECUTIVE SUMMARY
The Substance Abuse and Mental Health Services Administration (SAMHSA), Center
for Substance Abuse Prevention (CSAP) is accepting applications for fiscal year (FY)
2022 Harm Reduction Program Grants (Short Title: Harm Reduction). The purpose of
the program is to support community-based overdose prevention programs, syringe
services programs, and other harm reduction services. Funding will be used to enhance
overdose and other types of prevention activities to help control the spread of infectious
diseases and the consequences of such diseases for individuals with, or at risk of
developing substance use disorders (SUD), support distribution of opioid overdose
reversal medication to individuals at risk of overdose, build connections for individuals at
risk for, or with, a SUD to overdose education, counseling, and health education, refer
individuals to treatment for infectious diseases, such as HIV, sexually transmitted
infections (STIs), and viral hepatitis, and encourage such individuals to take steps to
reduce the negative personal and public health impacts of substance use or misuse.
This will include supporting capacity development to strengthen harm reduction
programs as part of the continuum of care. Recipients will also establish processes,
protocols, and mechanisms for referral to appropriate treatment and recovery support
services. Grantees will also provide overdose prevention education to their target
populations regarding the consumption of substances including but not limited to opioids
and their synthetic analogs. Funds may also be used to help address the stigma often
associated with risky behaviors and participation in harm reduction activities.
Funding Opportunity Title:

Harm Reduction Program Grant
(Short Title: Harm Reduction)

Funding Opportunity Number:

SP-22-001

Due Date for Applications:

February 7, 2022

Estimated Total Available Funding:

Up to $9,750,000 per year or
$29,250,000 over 3 years

Estimated Number of Awards:

25 awards

Estimated Award Amount:

Up to $400,000 per award per year

Cost Sharing/Match Required:

No

Anticipated Project Start Date:

May 30, 2022

Anticipated Award Date:

May 15, 2022

Length of Project Period:

Up to 3 years
4
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Eligible Applicants:

Eligible applicants are States; local, Tribal,
and territorial governments; Tribal
organizations; non-profit community-based
organizations; and primary and behavioral
health organizations [See Section III.1 for
complete eligibility information.]

Authorizing Statute

Section 516(a) of the Public Health
Services (PHS) Act, as amended and
Section 2706 of the American Rescue
Plan (ARP) Act.
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Be sure to check the SAMHSA website periodically for any updates on this
program.
All applicants MUST register with NIH’s eRA Commons in order to submit an
application. This process takes up to six weeks. If you believe you are
interested in applying for this opportunity, you MUST start the registration
process immediately. Do not wait to start this process.
WARNING: BY THE DEADLINE FOR THIS NOFO YOU MUST HAVE
SUCCESSFULLY COMPLETED THE FOLLOWING TO SUBMIT AN
APPLICATION:
• The applicant organization MUST be registered in NIH’s eRA Commons; AND
• The Project Director MUST have an active eRA Commons account (with the
PI role) affiliated with the organization in eRA Commons.
No exceptions will be made.
Applicants also must register with the System for Award Management (SAM) and
Grants.gov (See Appendix A – Application and Submission Requirements for all
registration requirements.)
DO NOT WAIT UNTIL THE LAST MINUTE TO SUBMIT THE APPLICATION. If you
wait until the last minute, there is a strong possibility that the application will not be
received without errors by the deadline.

I. PROGRAM DESCRIPTION
1. PURPOSE
The Substance Abuse and Mental Health Services Administration (SAMHSA), Center
for Substance Abuse Prevention (CSAP) is accepting applications for fiscal year (FY)
2022 Harm Reduction Program Grants (Short Title: Harm Reduction). The purpose of
the program is to support community-based overdose prevention programs, syringe
services programs, and other harm reduction services. Funding will be used to
enhance overdose and other types of prevention activities to help control the spread of
infectious diseases and the consequences of such diseases for individuals with, or at
risk of developing substance use disorders (SUD), support distribution of opioid
overdose reversal medication to individuals at risk of overdose, build connections for
individuals at risk for, or with, a SUD to overdose education, counseling, and health
education, refer individuals to treatment for infectious diseases such as HIV, sexually
transmitted infections (STIs), and viral hepatitis, and encourage such individuals to take
6
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steps to reduce the negative personal and public health impacts of substance use or
misuse. This will include supporting capacity development to strengthen harm reduction
programs as part of the continuum of care. Recipients will also establish processes,
protocols, and mechanisms for referral to appropriate treatment and recovery support
services. Grantees will also provide overdose prevention education to their target
populations regarding the consumption of substances including but not limited to opioids
and their synthetic analogs. Funds may also be used to help address the stigma often
associated with substance use and participation in harm reduction activities.
The priority populations for this program are rural communities, LGBTQ+ and/or racial
and ethnic minorities. Grant recipients will focus activities on “meeting people where
they’re at” within the context of harm reduction through integrating trauma-informed care
and facilitating the use of peer support workers in programming.
The Harm Reduction grant program is authorized under Section 516(a) of the PHS Act,
as amended and Section 2706 of the ARP Act of 2021.
2. KEY PERSONNEL
Key personnel are staff members who must be part of the project regardless of whether
they receive a salary or compensation from the project. These staff members must
make a substantial contribution to the execution of the project.
The Key Personnel for this program are the Project Director and the Peer Support
Worker. These position(s) require prior approval by SAMHSA after a review of
staff credentials and job descriptions.
3. REQUIRED ACTIVITIES
In Section C.1 of the Project Narrative, applicants must indicate the total number
of unduplicated individuals you expect to serve each year of the grant and over
the total project period. You are expected to achieve the numbers that are
proposed.
Project implementation is expected to begin by the fourth month of the grant.
These are the activities that every grant project must implement. Required activities
must be reflected in the Project Narrative in Section V of this NOFO.
Grant funds must be used primarily to support the following required harm reduction
activities:
• Assess organizational readiness and create a strategic action plan based upon
identified strengths, gaps (including those related to social determinants of
health), and opportunities for capacity development required to implement an
7
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evidence-based harm reduction program at the service delivery and
organizational levels. This strategic action plan should be developed by the
midpoint of Year 1 and will be supported by the Harm Reduction TA Center
(https://www.cdc.gov/harmreductionta/index.html).
• Develop a sustainability plan to ensure that harm reduction program elements
are continued after the grant period ends. This could include collaboration with
community partners to share resources or a cost sharing element.
• Develop policies and procedures to implement evidence-based trauma-informed
practices throughout each level of the organizational structure.
• Distribute opioid overdose reversal medication and deliver overdose prevention
education to target populations regarding the consumption of substances
including but not limited to opioids and their synthetic analogs.
• Establish processes, protocols, mechanisms for referral to treatment and
recovery support services, referral to treatment for infectious diseases such as
HIV, STIs, and viral hepatitis.
• Assemble a harm reduction advisory council that meets regularly to guide
program activities and project implementation. Group members should include
people who use drugs (PWUD), individuals in recovery, harm reduction service
providers and other key community members such as public safety officers,
mental health providers and treatment providers.
• Designate staff (e.g., Program Coordinator and/or Program Evaluator) to provide
program design, implementation, and evaluation to meet grant program and
reporting requirements.
• Purchase equipment and supplies to enhance harm reduction efforts, such as:
o Harm reduction vending machine(s), including stock for machines;
o Infectious diseases testing kits (HIV, HBV, HCV, etc.);
o Medication lock boxes;
o Naloxone kits (as well as higher dosages now approved by FDA);
o Safe sex kits, including PrEP resources and condoms;
o Safe smoking kits/supplies;
o Screening for infectious diseases (HIV, sexually transmitted infections, viral
hepatitis);
o Sharps disposal and medication disposal kits;
o Substance test kits, including test strips for fentanyl and other synthetic
drugs;
o Syringes to prevent and control the spread of infectious diseases;
o Vaccination services (hepatitis A, hepatitis B vaccination); and
o Wound care management supplies.
Harm reduction programs that use federal funding must adhere to federal, state, and
local laws, regulations, and other requirements related to such programs or services.
The Harm Reduction grant program is authorized under Section 2706 of the American
8
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Rescue Plan Act of 2021 which is not subject to the same syringe funding restrictions
as other federal grants.
4. ALLOWABLE ACTIVITIES
Grant funds may be used, but are not required, for the following allowable
activities:
• Hire and train staff to effectively deliver comprehensive harm reduction services,
including but not limited to mobile outreach, motivational interviewing techniques
and trauma-informed approaches to break the cycle of trauma.
• Implement a communication campaign focused on reducing stigma related to
harm reduction.
• Provide support services for individuals receiving harm reduction services,
including but not limited to screening, referral, linkage to care, and warm hand offs
to partner services focused on substance use and/or cessation, infectious
disease, mental health, primary care, housing, and other psychosocial needs.
• Utilize innovative approaches (i.e., overdose fatality review team and low threshold
buprenorphine induction) in harm reduction programs.
• Provide public education on any state “Good Samaritan” laws related to harm
reduction.
5. USING EVIDENCE-BASED PRACTICES
SAMHSA’s services grants are intended to fund services or practices that have a
demonstrated evidence base and that are appropriate for the population(s) of focus. An
evidence-based practice (EBP) refers to approaches to prevention, treatment, or
recovery that are validated by some form of documented research evidence. Both
researchers and practitioners recognize that EBPs are essential to improving the
effectiveness of treatment and prevention services. While SAMHSA realizes that EBPs
have not been developed for all populations and/or service settings, application
reviewers will closely examine proposed interventions for evidence base and
appropriateness for the population of focus.
To identify evidence-informed and culturally appropriate mental illness and substance
use prevention and treatment practices that can be implemented in your project,
applicants are encouraged to visit SAMHSA’s Evidence-Based Practice Resource
Center (www.samhsa.gov/ebp-resource-center), SAMHSA’s National Network to
Eliminate Disparities in Behavioral Health (NNED) (https://nned.net/), HHS’s Overdose
Prevention Strategy (https://www.hhs.gov/overdose-prevention/harm-reduction), CDC’s
Evidence-Based Strategies for Preventing Opioid Overdose
(https://www.cdc.gov/drugoverdose/pdf/pubs/2018-evidence-based-strategies.pdf), and
NIH’s Stigma and Discrimination Research Toolkit
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(https://www.nimh.nih.gov/about/organization/dar/stigma-and-discrimination-research
toolkit).
CDC’s Syringe Services Program Technical Package of Effective Strategies and
Approaches for Planning, Design, and Implementation.
https://www.cdc.gov/ssp/docs/SSP-Technical-Package.pdf
6. DATA COLLECTION/PERFORMANCE MEASUREMENT AND PROJECT
PERFORMANCE ASSESSMENT
Data Collection/Performance Measurement
All SAMHSA recipients are required to collect and report certain data so that SAMHSA
can meet its obligations under the Government Performance and Results (GPRA)
Modernization Act of 2010. You must document your plan for data collection and
reporting in your Project Narrative in response to Section D: Data Collection and
Performance Measurement in Section V of this NOFO.
Recipients will be required to report on the following indicators on a quarterly basis via
SAMHSA’s Performance Accountability and Reporting System (SPARS):
• Number of individual referrals to support services.
• Number of individual linkages to support services. For the purposes of this
indicator, “linkages” are defined as the number of engagements with any support
service. Each linkage should be counted (i.e., one individual participant engaged
with five individual support services should reflect five linkages).
• List and quantity of harm reduction materials purchased with grant funds
including, but not limited to:
o Harm reduction vending machine(s), including stock for machines; o
Infectious diseases testing kits (HIV, HBV, HCV, etc.);
o Medication lock boxes;
o Naloxone kits (as well as higher dosages now approved by FDA); o Safe
sex kits, including PrEP resources and condoms;
o Safe smoking kits/supplies;
o Screening for infectious diseases (HIV, sexually transmitted infections, viral
hepatitis);
o Sharps disposal and medication disposal kits;
o Substance test kits, including test strips for fentanyl and other synthetic
drugs;
o Syringes to prevent and control the spread of infectious diseases; o
Vaccination services (hepatitis A, hepatitis B vaccination); and
o Wound care management supplies.
• Evidence-based interventions or promising practices implemented at the
community level.
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• Organizational policy changes developed and/or implemented because of this
grant, including efforts made towards stigma reduction.
This information will be gathered using a uniform data collection tool provided by
SAMHSA. Recipients are required to submit data via SPARS and access will be
provided upon award. An example of the required data collection tool can be found
here https://www.samhsa.gov/grants/gpra-measurement-tools/csap-gpra. The
frequency of data reporting will be quarterly.
The collection of these data enables SAMHSA to report on key outcome measures
relating to the grant program. In addition to these outcomes, data collected by
recipients will be used to demonstrate how SAMHSA’s grant programs are reducing
disparities in access, service use, and outcomes nationwide.
An evaluation may be required to build the evidence base for this program. Grant
recipients may be required to participate fully in all aspects of the evaluation. This may
include collection of additional data and participation of sub-recipients. If applicable,
details on the evaluation, including type of evaluation and questions, will be provided.
Project Performance Assessment
Recipients must periodically review the performance data they report to SAMHSA (as
required above), assess their progress, and use this information to improve the
management of their grant project. Recipients are also required to report on their
progress addressing the goals and objectives identified in your Project Narrative.
The project performance assessment should be designed to help you determine
whether you are achieving the goals, objectives, and outcomes you intend to achieve
and whether adjustments need to be made to your project. Performance assessments
should also be used to determine whether your project is having/will have the intended
impact on behavioral health disparities.
Note: See Appendix E and Appendix F of this NOFO for more information on
responding to this section.
7. OTHER EXPECTATIONS
Behavioral Health Disparities
If your application is funded, you will be expected to develop a behavioral health
disparity impact statement no later than 60 days after your award. (See Appendix H –
Addressing Behavioral Health Disparities).
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Behavioral health equity refers to the right to access quality health care for all
populations regardless of the individual’s race, ethnicity, gender, socioeconomic status,
sexual orientation, or geographical location. This includes access to prevention,
treatment, and recovery services for mental and substance use disorders. Advancing
health equity involves ensuring that everyone has a fair and just opportunity to be as
healthy as possible. In conjunction with quality services, this involves addressing social
determinants of health (SDOH), such as employment and housing stability, insurance
status, proximity to services, culturally responsive care – all of which have an impact on
behavioral health outcomes.
The behavioral health disparity impact statement is in alignment with the expectations
related to Executive Order 13985 “Advancing Racial Equity and Support for
Underserved Communities Through the Federal Government.”
Tribal Behavioral Health Agenda
SAMHSA, working with tribes, the Indian Health Service, and National Indian Health
Board developed the first collaborative National Tribal Behavioral Health Agenda
(TBHA). Tribal applicants are encouraged to briefly cite the applicable TBHA
foundational element(s), priority(ies), and strategies that are addressed by their grant
application. The TBHA can be accessed at
http://nihb.org/docs/12052016/FINAL%20TBHA%2012-4-16.pdf.
Tobacco and Nicotine Free Policy
SAMHSA strongly encourages all recipients to adopt a tobacco/nicotine inhalation
(vaping) product-free facility/grounds policy and to promote abstinence from all tobacco
products (except in regard to accepted tribal traditions and practices).
Reimbursements for the Provision of Services
Recipients must utilize third party reimbursements and other revenue realized from the
provision of services to the extent possible and use SAMHSA grant funds only for
services to individuals who are not covered by public or commercial health insurance
programs, individuals for whom coverage has been formally determined to be
unaffordable, or for services that are not sufficiently covered by an individual’s health
insurance plan. Recipients are also expected to facilitate the health insurance
application and enrollment process for eligible uninsured clients. Recipients should also
consider other systems from which a potential service recipient may be eligible for
services (for example, the Veterans Health Administration or senior services), if
appropriate for and desired by that individual to meet his/her needs. In addition,
recipients are required to implement policies and procedures that ensure other sources
of funding are utilized first when available for that individual.
Behavioral Health for Military Service Members and Veterans
12
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SAMHSA encourages all recipients to address the behavioral health needs of active
duty military service members, veterans, and their families in designing and developing
their programs and to consider prioritizing this population for services, where
appropriate.
8. GRANTEE MEETINGS
All grantee meetings will be held virtually, and grantees are expected to fully participate
in these meetings. If SAMHSA elects to hold an in-person meeting, budget revisions will
be permitted.

II. FEDERAL AWARD INFORMATION
Funding Mechanism: Grant
Anticipated Total Available Funding: Up to $9,750,000 per year or $29,250,000 over
3 years
Estimated Number of Awards: 25 awards
Estimated Award Amount: Up to $400,000 per year per award Length of Project
Period: Up to 3 years
Proposed budgets cannot exceed $400,000 in total costs (direct and indirect) in
any year of the proposed project. Annual continuation awards will depend on the
availability of funds, recipient progress in meeting project goals and objectives, timely
submission of required data and reports, and compliance with all terms and conditions
of award.

III. ELIGIBILITY INFORMATION
1. ELIGIBLE APPLICANTS
The eligibility for this grant program is defined in Section 2706 of the American Rescue
Plan Act of 2021. Eligible applicants are:
• States;
• Local, tribal, and territorial governments;
• Tribal organizations;
• Non-profit community-based organizations; and
• Primary and behavioral health organizations.
It is recommended that you review information on eligibility in Appendix C.
13
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All non-profit entities must submit documentation of non-profit status in
Attachment 8.
Tribal organization means the recognized body of any AI/AN tribe; any legally
established organization of AI/ANs which is controlled, sanctioned, or chartered by such
governing body, or which is democratically elected by the adult members of the Indian
community to be served by such organization and which includes the maximum
participation of AI/ANs in all phases of its activities. Consortia of tribes or tribal
organizations are eligible to apply, but each participating entity must indicate its
approval. A single tribe in the consortium must be the legal applicant, the recipient of
the award, and the entity legally responsible for satisfying the grant requirements.
2. COST SHARING and MATCHING REQUIREMENTS
Cost sharing/match is not required in this program.

IV. APPLICATION AND SUBMISSION INFORMATION
1. ADDRESS TO REQUEST APPLICATION PACKAGE
The application forms package specific to this funding opportunity can be accessed
through Grants.gov Workspace or eRA ASSIST .
Due to difficulties with internet access, SAMHSA understands that applicants may
have a need to request paper copies of materials, including forms and required
documents. See Appendix A for more information obtaining an application package.
2. CONTENT AND FORM OF APPLICATION SUBMISSION
REQUIRED APPLICATION COMPONENTS:
The standard and supporting documents that must be submitted with the application
are outlined below and in Appendix A - 2.2 Required Application Components of this
NOFO.
All files uploaded as part of the application must be in Adobe PDF file format. See
Appendix B of this NOFO for formatting and validation requirements.
SAMHSA will not accept paper applications except under very special
circumstances. If you need special consideration, SAMHSA must approve the waiver
of this requirement in advance. See Appendix A - 4.2 Waiver of Electronic
Submission of this NOFO.
14
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• SF-424 – Fill out all Sections of the SF-424.
o In Line #4 (i.e., Applicant Identifier), input the Commons Username of the
PD/PI.
o In Line #17 input the following information: (Proposed Project Date: a. Start
Date: 5/30/2022; b. End Date: 5/29/2025).
• SF-424A BUDGET INFORMATION FORM – Fill out all Sections of the SF-424A
using instructions below. The totals in Sections A, B, and D must match.
o Section A – Budget Summary: If cost sharing/match is not required, use
the first row only (Line 1) to report the total federal funds (e) and
non-federal funds (f) requested for the first year of your project only.
o Section B – Budget Categories: If cost sharing/match is not required, use
the first column only (Column 1) to report the budget category breakouts
(Lines 6a through 6h) and indirect charges (Line 6j) for the total funding
requested for the first year of your project only.
o Section C – As cost sharing/match is not required for this program, leave
this section blank
Section D – Forecasted Cash Needs: Input the total funds requested, broken
down by quarter, only for Year 1 of the project period. Use the first row for
federal funds and the second row (Line 14) for non-federal funds.
o Section E – Budget Estimates of Federal Funds Needed for the Balance of
the Project: Enter the total funds requested for the out years (e.g., Year 2
and Year 3). For example, if you are requesting funds for three years in
total, enter the requested budget amount for each budget period in columns
b and c (i.e., 2 out years). - (b) First column is the budget for the second
budget period; (c) Second column is the budget for the third budget period.
Use Line 16 for federal funds and Line 17 for non-federal funds.
See Appendix B, to review common errors in completing the SF-424 and the
SF-424A. These errors will prevent your application from being successfully
submitted.
A link to a sample budget form and justification is provided in Appendix L –
Sample Budget and Justification of this document. It is highly
recommended that you use this sample budget format. This will expedite
review of your application.
• PROJECT NARRATIVE – (Maximum 10 pages total)
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The Project Narrative describes your project. It consists of Sections A through D.
(Remember that if your Project Narrative starts on page 5 and ends on page 15,
it is 11 pages long, not 10 pages.) More detailed instructions for completing each
section of the Project Narrative are provided in Section V.1 – Application Review
Information.
• BUDGET JUSTIFICATION AND NARRATIVE
The budget justification and narrative must be submitted as a file entitled “BNF”
(Budget Narrative Form) when you submit your application into Grants.gov. (See
Appendix A – 2.2 Required Application Components.)
• ATTACHMENTS 1 THROUGH 10
Use only the attachments listed below. If your application includes any
attachments not required in this document, they will be disregarded.
Do not use attachments to extend or replace any of the sections of the Project
Narrative. Reviewers will not consider them if you do.
Label the attachments as: Attachment 1, Attachment 2, etc. (Use the Other
Attachments Form if applying with Grants.gov Workspace or Other Narrative
Attachments if applying with eRA ASSIST.)
o Attachment 1: Letter of Commitment
Letters of Commitment from any organization(s) participating in the
proposed project. (Do not include any letters of support. Reviewers
will not consider them.)
o Attachment 2: Data Collection Instruments/Interview Protocols If you
are using standardized data collection instruments/interview protocols,
you do not need to include these in your application. Instead, provide a
web link to the appropriate instrument/protocol. If the data collection
instrument(s) or interview protocol(s) is/are not standardized, you must
include a copy in Attachment 2.
o Attachment 3: Sample Consent Forms
Forms to be submitted include, as appropriate, sample consent forms that
provide for: (1) informed consent for participation in service intervention;
(2) informed consent for participation in the data collection component of
the project; and (3) informed consent for the exchange (releasing or
requesting) of confidential information.
o Attachment 4: Project Timeline
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This attachment is scored by reviewers. Maximum of 2 pages. See
instructions in B.3 in Section V of this NOFO.
o Attachment 5: Biographical Sketches and Position Descriptions See
Appendix G for information on completing biographical sketches and job
descriptions. Position descriptions should be no longer than one page
each and biographical sketches should be two pages or less.
o Attachment 6: Letter to the Single State Agency (SSA) See Appendix
J – Intergovernmental Review (E.O. 12372) Requirements, of this NOFO;
If applicable.
o Attachment 7: Confidentiality and SAMHSA Participant Protection/
Human Subjects Guidelines
This attachment is in response to Appendix D of this NOFO and is a
required attachment.
o Attachment 8: Documentation of Nonprofit Status
Proof of nonprofit status must be submitted by private nonprofit
organizations with the application. Any of the following is acceptable
evidence of nonprofit status:
▪ A reference to the applicant organization’s listing in the Internal
Revenue Service’s (IRS) most recent list of tax-exempt organizations
described in section 501(c)(3) of the IRS Code;
▪ A copy of a currently valid Internal Revenue Service tax exemption
certificate;
▪ A statement from a State taxing body, State Attorney General, or other
appropriate state official certifying the applicant organization has a
non-profit status;
▪ A certified copy of the organization’s certificate of incorporation or similar
document that clearly establishes nonprofit status; or ▪ Any of the above
proof for a state or national parent organization and a statement signed
by the parent organization that the applicant organization is a local
nonprofit affiliate.
o Attachment 9: Form SMA 170 - Assurance of Compliance
with SAMHSA Charitable Choice Statutes and
Regulations
You are required to complete Form SMA 170 if your project is
offering substance use prevention or treatment services. This
form is posted on SAMHSA’s website at
http://www.samhsa.gov/grants/applying/forms resources.
o Attachment 10 - Population of Focus Certification
17
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You must include a written statement certifying that you are an applicant
with more than 50% of your total population(s) of focus, either individually
or collectively, belonging to rural, LGTBQ+ and/or racial/ethnic minority
communities, and include the percent of each population of focus. If not
applying as an applicant with more than 50% of your population of focus
belonging to rural, LGBTQ+, and/or racial/ethnic minority communities,
you do not need to submit this attachment.
3. UNIQUE ENTITY IDENTIFIER AND SYSTEM FOR AWARD MANAGEMENT
(SAM)
See Appendix A for information about the four registration processes that must be
completed including obtaining a Unique Entity Identifier and registering with the
System for Award Management (SAM). You must continue to maintain an active
SAM registration with current information during the period of time your organization
has an active federal award or an application under consideration by an agency
(unless you are an individual or federal agency that is exempted from those
requirements under 2 CFR § 25.110(b) or (c), has an exception approved by the
agency under 2 CFR § 25.110(d)).
4. APPLICATION SUBMISSION REQUIREMENTS
Applications are due by 11:59 PM (Eastern Time) on February 7, 2022. If an
organization is submitting more than one application, the project title should be
different for each application.
If you have been granted permission to submit a paper copy, the application must be
received by the above date and time. See Appendix A for information on how to
submit the application.

18

81
All applicants MUST register with NIH’s eRA Commons in order to submit an
application. This process takes up to six weeks. If you believe you are
interested in applying for this opportunity, you MUST start the registration
process immediately. Do not wait to start this process.
WARNING: BY THE DEADLINE FOR THIS NOFO YOU MUST HAVE
SUCCESSFULLY COMPLETED THE FOLLOWING TO SUBMIT AN
APPLICATION:
• The applicant organization MUST be registered in NIH’s eRA Commons;
AND
• The Project Director MUST have an active eRA Commons account (with
the PI role) affiliated with the organization in eRA Commons.
No exceptions will be made.
Applicants must also register with the System for Award Management (SAM) and
Grants.gov (see Appendix A for all registration requirements).
DO NOT WAIT UNTIL THE LAST MINUTE TO SUBMIT THE APPLICATION. If
you wait until the last minute, there is a strong possibility that the application will
not be received without errors by the deadline.

5. FUNDING LIMITATIONS/RESTRICTIONS
The funding restrictions for this project are as follows:
• No more than 20 percent of the total grant award for the budget period may be
used for:
o Administrative costs; and
o Data collection, performance measurement, and performance
assessment, including incentives for participating in the required data
collection follow-up.
• State recipients are required to use a minimum of 80 percent of their funds to
support subrecipient communities (the priority populations for this program are
rural communities, LGBTQ+ and/or racial and ethnic minorities) that
demonstrate a need for harm reduction programming in their selected
prevention priority(ies).
• Recipients must use funding to supplement and not supplant existing
prevention activities in their organization. The rule against supplanting
SAMHSA grant funds applies to activities funded by HRSA, CDC, CMS and
other federal programs.
19

82
Be sure to identify the expenses above in your proposed budget.
SAMHSA recipients must also comply with SAMHSA’s standard funding
restrictions, which are included in Appendix I – Standard Funding Restrictions.
6. INTERGOVERNMENTAL REVIEW (E.O. 12372) REQUIREMENTS
All SAMHSA grant programs are covered under Executive Order (EO) 12372, as
implemented through Department of Health and Human Services (HHS) regulation at 45
CFR Part 100. Under this Order, states may design their own processes for reviewing
and commenting on proposed federal assistance under covered programs. See
Appendix J for additional information on these requirements as well as requirements for
the Public Health System Impact Statement (PHSIS).
7. OTHER SUBMISSION REQUIREMENTS
See Appendix A for specific information about submitting your application.

V. APPLICATION REVIEW INFORMATION
In awarding Harm Reduction grants, SAMHSA will prioritize funding for programs which
address the needs of underserved populations, including rural communities, LGBTQ+,
and racial and ethnic minorities; and focus on communities that have been
disproportionately impacted by SUD.
1. EVALUATION CRITERIA
The Project Narrative describes what you intend to do with your project and includes the
Evaluation Criteria in Sections A-D below. Your application will be reviewed and scored
according to your response to the requirements in Sections A-E.
In developing the Project Narrative section of your application, use these instructions,
which have been tailored to this program.
• The Project Narrative (Sections A-E) together may be no longer than 10 pages.
• You must use the four sections/headings listed below in developing your Project
Narrative. You must indicate the Section letter and number in your
response, i.e., type “A-1”, “A-2”, etc., before your response to each
question. You do not need to type the full criterion in each section. You only
need to include the letter and number of the criterion. You may not combine two
or more questions or refer to another section of the Project Narrative in your
response, such as indicating that the response for B.2 is in C.7. Only
information included in the appropriate numbered question will be
20
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considered by reviewers. Your application will be scored according to how well
you address the requirements for each section of the Project Narrative.
• The number of points after each heading is the maximum number of points a
review committee may assign to that section of your Project Narrative. Although
scoring weights are not assigned to individual bullets, each bullet is assessed in
deriving the overall Section score.
• Any cost sharing proposed in your application will not be a factor in the evaluation
of your response to the Evaluation Criteria.
SECTION A: Population(s) of Focus and Statement of Need (20 points –
approximately 2 ½ pages)
1. Identify and describe your population(s) of focus and the geographic
catchment area where services will be delivered using relevant data (e.g.,
official data from federal, state or counties; organizational current and/or
historical service data, etc.). Provide a demographic profile of the
population(s) of focus in the catchment area in terms of race, ethnicity,
federally recognized tribe (if applicable), language, sex, gender identity,
sexual orientation, age, housing status, and other socioeconomic
indicators. Identify the source(s) of the data which support this section.
2. Describe how and why your organization has identified a need for harm
reduction services in your selected population(s) of focus, and how the
project will reach your population(s) of focus. When documenting the extent
of need, describe existing service gaps, health disparities and incidence of
poor health indicators influenced by social determinants of health. Use
relevant socioeconomic, psychosocial, and public health data to further
demonstrate the need for harm reduction services in the population(s) of
focus (e.g., healthcare utilization, current incidence and prevalence rates,
overdose data, etc.). Identify each source of data.
SECTION B: Bonus Points for Providing Services to Priority Populations (10
points – approximately ½ page)
An additional 10 points will be given to applicants with more than 50 percent of their
total population(s) of focus, either individually or collectively, belonging to rural,
LGTBQ+ and/or racial/ethnic minority communities.
1. Specify the percentage of your population of focus that will be served in each of
the following groups: rural, LGTBQ+, and racial and/or ethnic minority
communities. If you do not plan to provide services to more than 50 percent of
your total (individual or collectively for these population(s) of focus, indicate so in
your response.
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SECTION C: Proposed Implementation Approach (35 points – approximately 4
pages not including Attachment 4 – Project Timeline)
1. Describe the goals and measurable objectives (see Appendix E) of the
proposed project and align them with the Statement of Need described in
A.2. Provide the following table:
Projected Number of Unduplicated Individuals to be Reached with Grant
Funds
Year 1

Year 2

Year 3

Total

Number of service
encounters.
Number of referrals
to support services.
Number of linkages
to support services.*
*For the purposes of this indicator, “linkages” are defined as the number of
engagements with any support service. Each linkage should be counted (i.e., one
individual participant engaged with five individual support services should reflect
five linkages).
2. Describe how you will implement the Required Activities in Section
I.3 including your organizational harm reduction service delivery
model and addressing how your project will utilize culturally
informed strategies and evidence-based interventions.
3. Provide a table depicting a realistic timeline for the entire three years of
the project period showing dates, required activities, and responsible
staff. These key activities must include the required activities outlined in
Section I.3 [NOTE: Be sure to show that the applicant organization has
necessary resources in place so that the project can be implemented,
and service delivery can begin as soon as possible and no later than
four months after grant award. The timeline cannot be more than two
pages and should be submitted in Attachment 4.] The
recommendation of pages for this section does not include the timeline.
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SECTION D: Staff and Organizational Experience (20 points – approximately 2
page)
1. Discuss organizational background, purpose, and goals. Include the
organization’s annual operating budget, total number of staff, and services
provided.
2. Describe the historical and current capacity of the applicant organization to
implement harm reduction services to the population(s) of focus, including
previously related project successes and outcomes. Explain how your
organization measures their capacity and success. If applicable, identify other
organization(s) that will partner with the proposed project. Describe their
experience providing harm reduction services to the population(s) of focus,
and their specific roles and responsibilities for this project. Letters of
Commitment from each partner organization must be included in Attachment
1. Please indicate if there are no intended partnerships with other
organizations.
3. Provide a complete list of staff positions for the project, including the Key
Personnel (Project Director and Peer Support Worker). For each staff: list
their title, project role, level of effort, qualifications, program/service
experience, and familiarity with the culture and language of the population(s)
of focus.
Section E: Data Collection and Performance Measurement (15 points –
approximately 1 page)
1. Provide specific information about how the applicant organization will collect
the required data for this program and how such data will be utilized to
manage, monitor, and enhance the program. Describe the organizations
experience evaluating public health programs and which staff will be engaged
in data collection and quarterly reporting for this project.
2. BUDGET JUSTIFICATION, EXISTING RESOURCES, OTHER SUPPORT (other
federal and non-federal sources)
You must provide a narrative justification of the items included in your proposed budget,
as well as a description of existing resources and other support you expect to receive
for the proposed project. Other support is defined as funds or resources, whether
federal, non-federal, or institutional, in direct support of activities through fellowships,
gifts, prizes, in-kind contributions, or non-federal means. (This should correspond to
Item #18 on your SF-424, Estimated Funding.) Other sources of funds may be used for
unallowable costs, e.g., meals, sporting events, entertainment.
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An illustration of a budget and narrative justification is included in Appendix L – Sample
Budget and Justification. It is highly recommended that you use this sample budget
format. Your budget must reflect the required activities and funding
limitations/restrictions specified in Section IV.3. Specifically identify the items
associated with these costs in your budget.
3. REVIEW AND SELECTION PROCESS
SAMHSA applications are peer-reviewed according to the evaluation criteria
listed above.
Decisions to fund a grant are based on:
• The strengths and weaknesses of the application as identified by peer
reviewers. The results of the peer review are of an advisory nature. The
program office and approving official make the final determination for funding;
• SAMHSA will review and prioritize funding for programs which address the
needs of underserved populations, including rural communities, LGBTQ+,
and/or racial/ethnic minorities; and focus on communities that have been
disproportionately impacted by SUD;
• When the individual award is over $250,000, approval by the CSAP National
Advisory Council;
• Availability of funds;
• Equitable distribution of awards in terms of geography (including urban, rural
and remote settings) and balance among populations of focus and program
size;
• Submission of any required documentation that must be submitted prior to
making an award; and
• SAMHSA is required to review and consider any information about your
organization that is in the Federal Award Performance and Integrity Information
System (FAPIIS). In accordance with 45 CFR 75.212, SAMHSA reserves the
right not to make an award to an entity if that entity does not meet the
minimum qualification standards as described in section
75.205(a)(2). If SAMHSA chooses not to award a fundable application in
accordance with 45 CFR 75.205(a)(2), SAMHSA must report that
determination to the designated integrity and performance system accessible
through the System for Award Management (SAM) [currently the Federal
Awardee Performance and Integrity Information System (FAPIIS)]. You may
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review and comment on any information about your organization that that
federal awarding agency previously entered. SAMHSA will consider your
comments, in addition to other information in FAPIIS in making a judgment
about your organization’s integrity, business ethics, and record of
performance under federal awards when completing the review of risk posed
as described in 45 CFR 75.205 HHS Awarding Agency Review of Risk by
Applicants.

VI. FEDERAL AWARD ADMINISTRATION INFORMATION
1. FEDERAL AWARD NOTICES
You will receive an email from SAMHSA, via NIH’s eRA Commons, that will describe
the process for how you can view the general results of the review of your application,
including the score that your application received.
If your application is approved for funding, a NoA will be emailed to the following: 1) the
BO’s email address identified in the Authorized Representative section email field on
page 4 of the SF-424; and 2) the email associated with the Commons account for the
Project Director (section 8 Item f on page 2 of the SF-424). Hard copies of the NoA will
no longer be mailed via postal service. The NoA is the sole obligating document that
allows you to receive federal funding for work on the grant project. Information about
what is included in the NoA can be found at: https://www.samhsa.gov/grants/grants
management/notice-award-noa.
If your application is not funded, you will receive a notification from SAMHSA, via NIH’s
eRA Commons.
2. ADMINISTRATIVE AND NATIONAL POLICY REQUIREMENTS
If your application is funded, you must comply with all terms and conditions of the NoA.
SAMHSA’s standard terms and conditions are available on the SAMHSA website https://www.samhsa.gov/grants/grants-management/notice-award-noa/standard-terms
conditions. See Appendix K for specific information about administrative and national
policy requirements.
4. REPORTING REQUIREMENTS
Quantitative and qualitative data described in Section I.6 will be reported quarterly in
SPARS. In addition, you will be required to submit:
• An organizational readiness assessment at the midpoint of Year 1 (i.e. 6 months
post award);
• A strategic action plan to address gaps and build on strengths identified through
the organizational readiness assessment at the endpoint of Year 1; and
25
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• A quarterly progress report.
Quarterly progress reports must discuss project progress, including successes and
barriers encountered, and efforts to overcome these barriers. Refer to Section VI.1 for
any program specific information on the frequency of reporting and any additional
requirements.
A final performance report must be submitted within 120 days after the end of the final
budget period. The final performance report must be cumulative and report on all grant
activities during the entire project period. Refer to Section VI.3 for any program specific
information on the frequency of reporting and any additional requirements.
Grants Management:
Successful applicants must also comply with the following standard grants management
reporting requirements at https://www.samhsa.gov/grants/grants
management/reporting-requirements, unless otherwise noted in the NOFO or Notice of
Award (NoA).

VII. AGENCY CONTACTS
For program related and eligibility questions contact:
Cara Alexander
Center for Substance Abuse Prevention
Substance Abuse and Mental Health Services Administration
(240) 276-0578
DTPHarmReduction@samhsa.hhs.gov
For fiscal/budget related questions contact:
Office of Financial Resources, Division of Grants Management
Substance Abuse and Mental Health Services Administration
(240) 276-1400
FOACSAP@samhsa.hhs.gov
For grant review process and application status questions contact:
Sherresa Bailey-Jones
Office of Financial Resources, Division of Grant Review
Substance Abuse and Mental Health Services Administration
(240) 276-1359
sherresa.bailey@samhsa.hhs.gov
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APPENDIX C
Bethel University SAMHSA Harm Reduction Draft Submission
SECTION A: Population(s) of Focus and Statement of Need (20 points – approximately 2 ½
pages)
1. Identify and describe your population(s) of focus and the geographic catchment area
where services will be delivered using relevant data (e.g., official data from federal, state or
counties; organizational current and/or historical service data, etc.). Provide a
demographic profile of the population(s) of focus in the catchment area in terms of race,
ethnicity, federally recognized tribe (if applicable), language, sex, gender identity, sexual
orientation, age, housing status, and other socioeconomic indicators. Identify the source(s)
of the data which support this section.
The population of focus for the expansion of Clinic 555’s services is located in the
City of St. Paul and the greater Ramsey County area in Minnesota. The population of St.
Paul as of April 1st, 2020 was 311,527 people, equating to 5,484.3 people per square mile
(U.S. Census Bureau, 2020). Of those 311,527 people, 51.4% were White American,
16.1% Black or African American, 0.8% American Indian and Alaska Native, 18.7%
Asian, 9.2% Hispanic or Latino, and 4.9% identified as two or more races (U.S. Census
Bureau, 2020). The sex distribution in St. Paul in 2020 was 50.7% female and 49.3% male
(U.S. Census Bureau, 2020). In addition, 4.2% of the population identified as LGBTQ in a
2012-2017 survey (Conron et al., 2021). Minnesota has a rich American Indian history.
There are eleven federally recognized American Indian tribes in Minnesota, four of which
are located around the Twin Cities and metropolitan area (Minnesota Indian Affairs
Council, 2021). St. Paul itself is situated between the Shakopee Mdewakanton Sioux
Community and the Prairie Island Indian Community (Minnesota Indian Affairs Council,
2021).
St. Paul is home to residents that speak more than 100 languages and dialects (St. Paul
Department of Planning and Economic Development [PED], 2021). In 2020, the percentage of
people who spoke a language other than English at home in St. Paul was 29.9% (U.S. Census
Bureau, 2020). Those who had less than a Bachelor's degree education level was 59.2% (U.S.
Census Bureau, 2020). The per capita income in 2019 in St. Paul was $31,242 with 18.9% of
people in poverty (U.S. Census Bureau, 2020). Those without health insurance in St. Paul (under
the age of 65) in 2020 made up 7.2% of the population (U.S. Census Bureau, 2020). A disparity
is evident when comparing the percentage of people that were unemployed in St. Paul in 2021
based on race – 4.2% of unemployed individuals were White American compared to 13.1% of
unemployed were Black or African American (St. Paul PED, 2021). When broken down by race,
the per capita income in 2021 estimates that White Americans earned $42,874 whereas Black or
African American individuals earned $15,577 (St. Paul PED, 2021). Homeownership also shows
a distinct difference based on race – 61.2% for White Americans and 16.9% for Black or African
Americans. Further, households that pay more than 30% of their income for housing were split
30.6% for White Americans and 52.4% for Black or African Americans (St. Paul PED, 2021).
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As of January 2020, there were an estimated 7,940 people experiencing homelessness on
any given day in Minnesota (United States Interagency Council on Homelessness, 2020).
Minorities are at greater risk of experiencing homelessness in Ramsey County. In 2018 it was
found that African Americans were eight times more likely and American Indian individuals
were 13 times more likely to be homeless compared to their White American counterparts
(Ramsey County, 2022). Between the 2018-2019 school year, approximately 17,071 public
school students experienced homelessness during the year (United States Interagency Council on
Homelessness, 2020). The numbers of people who were experiencing homelessness in St. Paul
in 2020 was significantly impacted by the COVID-19 pandemic. According to the St. Paul
Department of Emergency Management, more residents have been sheltering in unsafe
conditions such as tents, bridges, and caves as a result of the economic impacts of the pandemic
(2021). Emergency shelter use increased in 2020 due to the pandemic with approximately two
and a half times more people using them at some point during the year (Ramsey County, 2022).
While the catchment area for this proposal includes the greater Ramsey County area and
the City of St. Paul, injection drug users (IDUs) are the specific population of focus for Clinic
555’s expansion of harm reduction services. According to SAMHSA in the National Survey on
Drug Use and Health Report (2012), 15.7% of people aged 12 and older in the Minneapolis-St.
Paul-Bloomington area reported any illicit drug use compared to the Minnesota average of
14.0% and the national average of 14.7%. In 2019, there were 413 opioid-related drug overdose
deaths in Minnesota (Minnesota Department of Health [MDH], 2020c). This mortality rate is
disproportionately impacting people of color. For Minnesota, African Americans are two times
more likely to die of a drug overdose than White Americans, and American Indians are seven
times more likely to die of a drug overdose than White Americans (MDH, 2019). In 2018, the
race disparity in drug overdose mortality rates in Minnesota between American Indians and
White Americans was the largest in the United States, with African Americans and White
Americans being the second largest (MDH, 2019). The differences in overdose rates among
people of color are largely due to systemic oppression and inequitable access to care (MDH,
2019).
2. - Describe how and why your organization has identified a need for harm reduction
services in your selected population(s) of focus, and how the project will reach your
population(s) of focus. When documenting the extent of need, describe existing
service gaps, health disparities and incidence of poor health indicators influenced by
social determinants of health. Use relevant socioeconomic, psychosocial, and public
health data to further demonstrate the need for harm reduction services in the
population(s) of focus (e.g., healthcare utilization, current incidence and prevalence
rates, overdose data, etc.). Identify each source of data.
For Minnesota, data from the Minnesota Department of Health (MDH) Opioids Drug
Overdose Dashboard, updated August 2021, show that opioid-related deaths have substantially
increased since 2000. Specifically, in 2020, there were 678 opioid related deaths, a 196%
increase from the 229 reported in 2010. Although the number of opioid prescriptions dispensed
has consistently decreased since 2015, emergency room visits for non-fatal overdoses
substantially increased from the 1,618 in 2017, with a reported 3,990 cases in 2020, representing
a 146% increase (MDH, 2021). The prevalence of opioid use is further indicated by the data
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showing that there were two hospital admissions, six emergency department visits, and seven
Emergency Medical Services (EMS) responses related to opioid overdose for every one opioid
overdose fatality (MDH, 2020c). Opioid overdose deaths have also continued to climb in
Ramsey county specifically (MDH, 2020a). Data shows there were 24 opioid involved overdose
deaths in 2018, 33 deaths in 2019 and preliminary numbers show 69 deaths for 2020. Ramsey
county also had the highest number of drug overdose deaths in the state for the years 2010-2020,
with 379 deaths reported. Further, 550 non-fatal overdose hospital visits occurred in Ramsey
county in 2020 alone (MDH, 2020d).
Since intravenous drug users (IDUs) are at higher risk for contracting diseases such
as hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus
(HIV), further harm reduction strategies are justified (Center for Disease Control and
Prevention, 2021). According to the MDH HIV Incidence Report, of the 226 new cases of
HIV reported in Minnesota in 2020, 38 of those cases were located in Ramsey county
(MDH, 2020b). One of the main harm reduction strategies that Clinic 555 currently
implements is a fixed structural syringe service program (SSP). A study conducted by the
CDC from 1988 to 1993 showed a 11% decrease in HIV annual seroprevalence in cities
with SSPs and a report from New Haven, Connecticut documented a 24% drop in HIV
seroprevalence after the city implemented an SSP (Hurley et al., 1997; Pollack et al.,
2002). Further, IDUs that visit SSPs have shown a lower likelihood to contract HBV and
HCV (Hagan et al., 1995). Cities with SSPs also have significantly less contaminated
needles found in public areas (Tookes et al., 2012). Finally, SSPs have been particularly
effective in helping IDUs get connected to drug abuse and addiction treatment programs
(Hagan et al., 2000). A SSP in Seattle reported their clients were five times more likely to
undergo treatment programs compared to IDUs that did not use their SSP. IDUs who use
SSPs have also shown more likelihood to maintain their sobriety (Hagan et al., 2000;
Strathdee et al., 1999).
However, while the successes of SSPs have proven incredibly beneficial in harm
reduction, IDUs have significantly poorer social determinants of health and adverse care
outcomes, supporting the need for further development and expansion of services. A
national study of IDUs conducted by Matsuzaki et al. (2018), demonstrated that of the
study IDU participants, 17% were uninsured and 29% reported sometimes going without
the medical care needed because it was too expensive. It was reported that 35% of study
IDU participants had less than a high school degree in comparison to 11.6% of the general
U.S. population. Further, more than 18% of IDUs in the study reported having been treated
poorly at a clinic in the past, compared to 14% for non-substance using counterparts. A
higher proportion of the IDU participants (21%) reported mistrust in doctors compared to
the non-using counterparts. Additionally, lack of transportation was a commonly reported
barrier in the study population (Matsuzaki et al., 2018).
In order to better serve IDUs, the implementation of more efficient harm reduction
means is proposed, specifically, the addition of a mobile SSP to expand the area of service
Clinic 555 offers. Clinic 555 currently offers HIV testing, HIV prevention education
including pre-exposure prophylaxis (PrEP), post exposure prophylaxis (PEP), clean needle
exchanges, naloxone kit distribution, fentanyl test strips, overdose prevention education,
sexual and reproductive health services, and wound care services (Ramsey County, 2021).
This mobile unit will act as an extension of the fixed SSP by bringing a mobile SSP to
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IDUs who are unable to utilize Clinic 555’s services due to barriers. As mentioned above,
one barrier facing IDUs was mistrust in traditional medical providers and settings.
According to Moore et al. (2012), a mobile SSP in Baltimore was shown to help overcome
this barrier. IDU’s utilizing the mobile SSP in Baltimore reported previous poor treatment
by clinicians in traditional clinic settings. As a result of the clientele’s previous
experiences, patients reported they were more likely to return to the mobile SSP for
continued care but would not attend a traditional fixed clinic appointment even after being
referred (Moore et al., 2012).
Another barrier that can be addressed by the mobile aspect of the proposed SSP is
the lack of transportation reported by many IDU clientele. This barrier was demonstrated
by a syringe exchange program in Oakland, California, which reported 84.8% of patients
live within just ten miles of the clinic (Grau et al., 2002). Another SSP in Montreal, Canada
demonstrated the dependence and importance of physical distance to services. A study
conducted by de Montigny et al. in 2010 did not have mobile units, but showed this
dependence on distance by using needle drop boxes to receive dirty needles. The use of the
drop boxes decreased by almost half the farther the clients had to walk to use the boxes (de
Montigny et al., 2010). This indicates that distance between access to clean needles for
IDUs directly affects whether the service provided is utilized. The flexibility of mobilizing
Clinic 555’s current services to reach underserved populations in the greater Ramsey
County area and St. Paul is crucial for the care of IDUs, minorities, and low income
populations. These communities will benefit from having better access to public health
services, an alternative clinic setting, and a SSP (Bennet et al., 2020).

SECTION B: Bonus Points for Providing Services to Priority Populations (10
points – approximately ½ page)
An additional 10 points will be given to applicants with more than 50 percent of
their total population(s) of focus, either individually or collectively, belonging to
rural, LGTBQ+ and/or racial/ethnic minority communities.
1. Specify the percentage of your population of focus that will be served in each of
the following groups: rural, LGTBQ+, and racial and/or ethnic minority
communities. If you do not plan to provide services to more than 50 percent of
your total (individual or collectively for these population(s) of focus, indicate so
in your response.
Clinic 555’s ongoing fixed syringe service program (SSP) currently serves
approximately 55% White American clients (Zander, H. Personal communication. 20,
January 2022). One of the goals of the program is to help combat the significant racial
disparities within the target population by increasing the number of racially and ethnically
diverse clients with the proposed mobile SSP. The Minnesota Department of Health
(MDH) has shown that while the state has one of the lowest rates of drug overdose
mortality in the United States, the racial disparity of fatalities from overdose is some of
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the worst in the nation. According to the MDH, as of 2019, American Indians are seven
times as likely to die from a drug overdose as White Americans, and African Americans
are twice as likely to die compared to their white counterparts. This data represented the
largest race disparity in the nation for American Indians and the second greatest disparity
for African Americans when compared to other states' rates of racial disparity in 2018
(Minnesota Department of Health, 2019).
Data from national Mobile Health Clinics (MHCs) show that they serve a
statistically higher proportion of racial and ethic minorities compared to traditional
fixed-structured facilities (Bennet et al., 2020). A national analysis of MHCs conducted in
2020 by Bennet et al. found that while 13.4% of the general population identified as
African American according to the 2010 U.S. Census, the average percentage of clients
identifying as African American utilizing MHCs was 35%. In addition, while only 18.3%
of the 2010 U.S. census respondents identified as Latino or Hispanic, data in this study
found that the average percentage of clients utilizing MHCs who identified as Hispanic or
Latino was 26.6% (Bennet et al., 2020). Using data surrounding the population of St. Paul
from the Department of Planning and Economic Development (2021), population density
maps as seen in Figure 1 are representative of how a mobile SSP can target and access
higher proportions of POC relative to the fixed site. The current fixed SSP of Clinic 555 is
located in Census Tract 342.01 which represents a percentage of 71.9% White American,
12.9% African American, 10.4% Asian American, 0.6% Native American and 0%
Hispanic American. However, neighboring census blocks show dramatically increased
proportions of racial diversity. For example, Census Tract 336 represents 71.4% African
American, 18.1% Asian American, 1.9% Hispanic American and 4.9% White American.
Census Tract 317.02 represents 27.9% African American, 24.4% Asian American, 19.2%
Hispanic American, 2.3% Native American and 19.8% White American. Using population
data, it is easily seen that a proposal of a mobile SSP will drastically increase access and
service to areas of higher ethnic and racial minorities (St. Paul Department of Planning
and Economic Development, 2021).
Figure 1
Racial and Ethnic Composition of Saint Paul Residents

Note: source from 2020 Census Redistricting Data and Saint Paul Department of Planning & Economic
Development analysis. Racial and Ethnic Composition is per census block
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APPENDIX D
Completed SAMHSA Harm Reduction Grant Application - Clinic 555
SAMHSA GRANT – PROJECT NARRATIVE Saint Paul – Ramsey County Public Health
SECTION A: Population of Focus and Statement of Need
A-1
The population of focus for the expansion of Clinic 555’s harm reduction services is
located in St. Paul and the greater Ramsey County area in Minnesota (MN). According to the
2020 U.S. Census, the population of St. Paul is estimated at 311,527 people, equating to 5,484
people per square mile. Of those, 51.4% are White, 16.1% Black, 0.8% Native American and
Alaska Native, 18.7% Asian, 9.2% Hispanic, and 4.9% two or more races. The sex distribution in
St. Paul in 2020 was 50.7% female and 49.3% male (U.S. Census, 2020). In addition, 4.2% of
the population identified as LGBTQ in a 2012-2017 survey (Conron et al., 2021). St. Paul is
situated between the Shakopee Mdewakanton Sioux Community and the Prairie Island Indian
Community (Minnesota Indian Affairs Council, 2021).
St. Paul is home to residents that speak more than 100 languages and dialects (St. Paul
Department of Planning and Economic Development [PED], 2021). In 2020, the percentage of
people who spoke a language other than English at home was 29.9% (U.S. Census, 2020). Those
who had less than a bachelor's degree education level was 59.2% (U.S. Census, 2020). The per
capita income in 2019 was $31,242 with 18.9% of people in poverty (U.S. Census, 2020). Those
without health insurance in St. Paul (under the age of 65) in 2020 made up 7.2% of the
population (U.S. Census, 2020). A disparity is evident when comparing the percentage of people
that were unemployed in St. Paul in 2021 based on race: 4.2% of unemployed individuals were
White compared to 13.1% being Black (St. Paul PED, 2021). When broken down by race, the
per capita income in 2021 estimates that Whites earned $42,874 whereas Blacks earned $15,577
(St. Paul PED, 2021). Homeownership also shows a distinct difference based on race: 61.2% for
Whites and 16.9% for Blacks. Further, households that pay more than 30% of their income for
housing were split 30.6% for Whites and 52.4% for Blacks (St. Paul PED, 2021).
As of January 2020, there were an estimated 7,940 people experiencing homelessness on
any given day in Minnesota (U.S. Interagency Council on Homelessness, 2020). Racially and
ethnically diverse communities are at greater risk of experiencing homelessness in Ramsey
County. In 2018, Blacks were eight times more likely and Native Americans were 13 times more
likely to be homeless compared to Whites (Ramsey County, 2022). Between the 2018-2019
school year, approximately 17,071 public school students experienced homelessness during the
year (U.S. Interagency Council on Homelessness, 2020). The numbers of people who were
experiencing homelessness in St. Paul in 2020 was significantly impacted by the COVID-19
pandemic. According to the St. Paul Department of Emergency Management, more residents
have been sheltering in unsafe conditions such as tents, bridges, and caves as a result of the
economic impacts of the pandemic (2021). Emergency shelter use increased in 2020 due to the
pandemic with approximately two and a half times more people using them at some point during
the year (Ramsey County).
While the geographic focus area includes the greater Ramsey County area and the City of
St. Paul, people who use drugs (PWUDs) are the specific population of focus for Clinic 555’s
expansion of harm reduction services. According to SAMHSA in the National Survey on Drug
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Use and Health Report (2012), 15.7% of people aged 12 and older in the Minneapolis-St.
Paul-Bloomington area reported any illicit drug use compared to the Minnesota average of
14.0% and the national average of 14.7%. In 2019, there were 413 opioid-related drug overdose
deaths in Minnesota (Minnesota Department of Health [MDH], 2020). This mortality rate
is disproportionately impacting racially and ethnically diverse communities. In Minnesota,
Blacks are twice as likely to die of a drug overdose than Whites, and Native Americans are seven
times more likely to die of a drug overdose than Whites (MDH, 2019). In 2018, the race disparity
in drug overdose mortality rates in Minnesota between Native Americans and Whites was the
largest in the U.S., with the disparity between Blacks and Whites being the second largest in the
U.S. (MDH, 2019). The differences in overdose rates among people of color is largely due to
systemic oppression and inequitable access to care (MDH, 2019).
A-2
For Minnesota, data from the MDH Drug Overdose Dashboard, show that opioid-related
deaths have substantially increased since 2000. Specifically, in 2020, there were 678 opioid
related deaths, a 196% increase from the 229 reported in 2010. Deaths are only a glimpse of the
issue. Data show that generally, for each opioid overdose fatality, there are two hospital
admissions, six emergency department visits, and seven Emergency Medical Services (EMS)
responses (MDH, 2020c). Although the number of opioid prescriptions dispensed has
consistently decreased since 2015, emergency room visits for non-fatal overdoses in Minnesota
increased 146%. In 2017 it was 1,618, and that increased to 3,990 cases in 2020 (MDH, 2021).
Opioid overdose deaths have also continued to climb in Ramsey County. Data shows
there were 23 opioid involved overdose deaths in 2018, 32 deaths in 2019 and 69 deaths in 2020.
Ramsey county had the second highest number of drug overdose deaths in the state for the years
2010-2020, with 379 deaths reported (MDH, 2020a). Further, 550 non-fatal overdose hospital
visits occurred in Ramsey County in 2020 alone (MDH, 2020d).
Since people who inject drugs (PWIDs) are at higher risk for contracting diseases such as
hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV),
further harm reduction strategies are justified (CDC 2021). According to the MDH HIV
Incidence Report, of the 226 new cases of HIV reported in Minnesota in 2020, 38 of those
cases were located in Ramsey County (MDH, 2020b). One of the main harm reduction strategies
that Clinic 555 currently implements is a fixed site syringe service program (SSP). A study
conducted by the CDC from 1988 to 1993 showed a 11% decrease in HIV annual seroprevalence
in cities with SSPs, and a report from New Haven, Connecticut documented a 24% drop in HIV
seroprevalence after the city implemented a SSP (Hurley et al., 1997; Pollack et al., 2002).
Further, PWUDs that visit SSPs have shown a lower likelihood to contract HBV and HCV
(Hagan et al., 1995). Cities with SSPs also have significantly less contaminated needles found in
public areas (Tookes et al., 2012). Finally, SSPs have been particularly effective in
helping PWIDs get connected to drug abuse and addiction treatment programs (Hagan et al.,
2000). A SSP in Seattle reported their clients were five times more likely to undergo treatment
programs compared to PWIDs that did not use their SSP. PWUDs who use SSPs have also
shown greater likelihood to maintain their sobriety (Hagan et al., 2000; Strathdee et al., 1999).
However, while the successes of SSPs have proven incredibly beneficial in harm
reduction, PWIDs have significantly poorer social determinants of health and adverse care
outcomes, supporting the need for further development and expansion of services. A national
study of PWIDs conducted by Matsuzaki et al. (2018), demonstrated that of the study injection
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drug use (IDU) participants, 17% were uninsured and 29% reported sometimes going without the
medical care needed because it was too expensive. It was reported that 35% of study IDU
participants had less than a high school degree in comparison to 11.6% of the general U.S.
population. Further, more than 18% of PWIDs in the study reported having been treated poorly at
a clinic in the past, compared to 14% of non-substance using counterparts. A higher proportion
of the IDU participants (21%) reported mistrust in doctors compared to the non-using
counterparts. Additionally, lack of transportation was a commonly reported barrier in the study
population (Matsuzaki et al., 2018).
In order to better serve PWUDs, the implementation of more efficient harm reduction
means is proposed, specifically, the addition of a mobile SSP to better target
the diverse communities and geographic location Clinic 555 serves. Clinic 555 currently offers
HIV testing, HIV prevention education including pre-exposure prophylaxis (PrEP) and post
exposure prophylaxis (PEP), clean needles/syringes, naloxone kit distribution, fentanyl test
strips, overdose prevention education, sexual and reproductive health services, and wound care
services. This mobile unit will be a vehicle provided by Ramsey County. It will act as an
extension of the fixed SSP by bringing mobile SSP services to PWUDs who are unable to utilize
Clinic 555’s services due to barriers. As mentioned above, one barrier facing PWUDs was
mistrust in traditional medical providers and settings. According to Moore et al. (2012), a mobile
SSP in Baltimore was shown to help overcome this barrier. PWIDs utilizing the mobile SSP in
Baltimore reported previous poor treatment by clinicians in traditional clinic settings. As a result
of their previous experiences, patients reported they were more likely to return to the mobile SSP
for continued care but would not attend a traditional fixed clinic appointment even after being
referred (Moore et al., 2012). Another barrier that can be addressed by the mobile aspect of the
proposed SSP is the lack of transportation reported by many PWUD clientele. The flexibility of
mobilizing Clinic 555’s current services to reach underserved populations in the greater Ramsey
County area and St. Paul is crucial for the care of PWUDs, racially and ethnically diverse, and
low-income populations. These communities will benefit from having better access to public
health services, an alternative setting for clinical services, and a SSP (Bennet et al., 2020).
SECTION B: Bonus Points for Providing Service to Priority Populations
The Syringe Services Program (SSP) is a program through Clinic 555, which has decades
of experience providing culturally relevant services in racial and ethnic communities. In 2020,
68% of Clinic 555 clients were from racially and ethnically diverse communities, with 45%
identifying as Black according to Family Planning Annual Report (FPAR) data. When looking at
the number of HIV tests done through the existing SSP, it is clear most clients served belong to a
racial and/or ethnic community. In 2020, the SSP performed 371 HIV tests. 63% of tests were
among racially and ethnically diverse people, with 49% of tests among Native Americans. In
2021, of the 377 HIV tests completed, 51% of tests were among people of color, with 38% of
tests among Native Americans. While some SSP client data by race are uncollected or
unknown, SSP staff is confident the current population of individuals served is more than 50%
racial and/or ethnic minority communities. Through the initiation of a mobile syringe exchange
with a delivery zone comprised of only zip codes scoring the highest in diversity (see Figure 1
map in Attachment 10), the program will continue to address the significant racial disparities
relating to drug overdose mortality especially among Blacks and Native Americans. For
example, St. Paul Census Tract 336 represents 71.4% Black, 18.1% Asian, 1.9% Hispanic and
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4.9% White. Census Tract 317.02 represents 27.9% Black, 24.4% Asian, 19.2% Hispanic, 2.3%
Native American and 19.8% White.
Priority Populations
Rural
LGBTQ
Racial and/or ethnic minority

Percent Population Served
NA – Ramsey County is urban
NA – Data not collected
60%

SECTION C: Proposed Implementation Approach
C-1
Goal #1: Establish mobile syringe exchange program to deliver comprehensive harm
reduction services, focusing on specific zip codes with racial and ethnic diverse
communities.
Objectives for Goal #1:
1.
By September 2022, staff will begin mobile syringe exchange two days each
week, reaching a minimum of 20 clients per week.
2.
In year two, the mobile syringe exchange will increase to three days each
week, reaching a minimum of 60 clients per week.
3.
In year three, the mobile syringe exchange will continue to provide deliveries
three days each week, reaching a minimum of 60 clients per week.
4.
Quarterly, the Program Coordinator will collect data on delivery locations to
ensure that 90% of deliveries take place in specific zip codes with racial and
ethnically diverse communities.
Goal #2: Expand and improve access to harm reduction supplies for clients accessing the
fixed-site SSP and mobile syringe exchange, including naloxone kits, fentanyl testing strips,
safe smoking supplies, and safe injection supplies, to decrease opioid overdose
mortality. Objectives for Goal #2:
1.
By August 2022, 100% of clients will have access to intramuscular and nasal
naloxone.
2.
By August 2022, 100% of clients will have access to fentanyl testing strips.
3.
By August 2022, 100% of clients will have access to safe smoking kits.
4.
By August 2022, 100% of clients will be able to receive as many syringes as
needed.
5.
By year 2, the Harm Reduction Advisory Council will review and make
changes to 100% of educational materials distributed to clients.
6.
Quarterly, the Program Coordinator will collect data on encounters to ensure
that over 50% of individuals receiving harm reduction supplies represent racial and
ethnic communities.
Goal #3: Increase number of successful community referrals, assuring linkages for clients
accessing the fixed site SSP and mobile syringe exchange.
Objectives for Goal #3:
1.
By August 2022, 100% of program staff will be trained on new data collection
tools to track community referrals and linkages within the existing SSP database.
2.
By September 2022, 100% of community referrals and linkages will be
entered into the existing SSP database.
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3.
Quarterly, the Program Coordinator will review data on referrals and linkages
to ensure that 100% of returning clients who were given a referral were provided
follow-up regarding linkage completion.
4.
Quarterly, the Peer Specialist will review existing community referral lists,
including mental health providers, MAT providers, substance use disorder
treatment facilities, and housing/shelter resources, to ensure updated information.
Projected Number of Unduplicated Individuals to be Reached with Grant Funds
Year 1
Year 2
Year 3
Total
Number of service
2234
3270
3270
8774
encounters.
Number of referrals to support 446
654
654
1754
services.
Number of linkages to support 35
80
80
195
services. *

C-2
Clinic 555’s SSP was developed in accordance with best practice as outlined by the Harm
Reduction Coalition’s Guide to Developing and Managing Syringe Access Programs (National
Harm Reduction Coalition, 2021). All SSP services are grounded in harm reduction principles.
Services are client-centered, non-judgmental, and non-coercive and aim to prevent negative
outcomes and encourage less risky behaviors associated with drug use through meeting
individuals “where they are”. For example, services are anonymous, there are no requirements to
receiving supplies, and client feedback is routinely solicited to guide program
development, Staff provide supplies and syringe cleanup at outreach locations, including wet
houses and encampments. Services are culturally informed with respect to race, ethnicity, gender,
sexual orientation, age, language, and literacy. All program materials are reviewed by a
community committee. Additionally, the SSP has population-specific resource guides (ex: a list
of mental health providers who focus on men who have sex (MSM) and use
drugs). Clinic 555 has also been selected to participate in the Title X funded Trauma Informed,
Resilience Oriented and Equitable Care (TIROE) project through the Reproductive Health
National Training Center (RHNTC). The clinic is partnering with the Ramsey County SOS
Sexual Violence Services (SOS) on this initiative to identify and incorporate trauma-informed
and inclusive care provision values that benefit clients. The proposed activities in this grant will
be subject to the same harm reduction and culturally informed standards that guide our existing
services.
The proposed activities are evidence-based to implement harm reduction strategies with
proven effectiveness. SSPs have an established record of decreasing the prevalence of
bloodborne pathogens, HIV, and hepatitis, and increasing the likelihood that individuals enter
substance use disorder treatment (Hagan et al., 2000; Hurley et al., 1997; Pollack et al., 2002;
Strathdee et al., 1999). We aim to establish a mobile SSP to reach individuals that are unable to
access the fixed site SSP, prioritizing zip-codes with racial and ethnic communities. The
mobile SSP will establish a delivery zone and respond to client telephone requests for delivery of
supplies to their homes. The delivery zone will encompass the following zip codes: 55106,
55107, 55104, 55103, 55119, and 55117. These zip codes score highest in diversity according to
the racial/ethnic diversity index established using 2020 census date (St. Paul Department of
Planning and Economic Development, 2021). The mobile SSP, which will operate out of Ramsey
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County vehicles, will have the flexibility to schedule stops at public locations as determined by
need and coordination with community partners.
Studies have shown that mobile SSPs serve communities not covered by existing
services, including individuals who report higher frequency and higher risk injection practices,
individuals with disabilities, and individuals who did not want to go to fixed site SSPs (Strike et.
al., 2018). Because there is only one fixed site SSP in St. Paul, the mobile SSP will
expand residents’ access to harm reduction services. The mobile SSP will run at times when the
fixed site SSP is closed, including Friday afternoons, evenings, and weekends. All vehicles will
be equipped to properly transport used syringes to allow safe disposal of equipment. Studies
have shown over 50% return rate of used syringes through mobile SSP (Strike et. al.,
2018). Our fixed-site SSP averages a 24% return rate. The increase in safe disposal through
mobile SSP is likely because clients do not need to transport syringes and fear intervention from
law enforcement.
Mobile SSPs have been found to shield clients from police, while providing a safe
opportunity for harm reduction interaction between clients and staff (Strike et. al., 2018). This is
important since the mobile SSP will prioritize diverse neighborhoods, which have increased
police presence and surveillance. Last, due to the nature of mobile SSPs, we anticipate shorter
interactions with clients where the focus is providing sterile equipment. However, staff are
trained to provide HIV, HCV, and STD testing in outreach/non-clinical locations, and these
services will be available to mobile SSP clients. If staff are unable to provide additional
services, mobile SSPs have been shown to successfully deliver effective referrals for medical
needs and substance use disorder treatment (Strike et. al., 2018). We envision the
mobile SSP complementing our fixed site SSP, with staff making active referrals for wraparound
services such as HIV, HCV, and STD testing and linkage to care, wound care,
vaccinations, MAT, and PrEP. As needed, staff will establish new referral procedures with
community service providers.
To further complement our existing harm reduction services, we aim to purchase supplies
for safe smoking and snorting. Research points to inhalation as a safer mode of drug
consumption than injection, showing lower rates of drug dependency, decreased risk of
infectious disease transmission, decreased overdose risk (in some settings), and lower rates of
physical and psychological concerns (Bardwell et. al, 2021). Additionally, SSP clients report a
preference to smoke drugs on especially cold days due to difficulty finding veins and increased
likelihood of missed shots. This can lead to vascular damage and infections. Having safe
injection and safe inhalation supplies will give clients the ability to choose their method of drug
consumption considering their personalized harm reduction practices. One study found the
provision of foils lead to two-thirds of study participants choosing to smoke heroin instead of
injecting it (Stöver et. al., 2014). The same study recommended the use of high-quality
prevention kits to increase likelihood of acceptance, including pre-cut foils and information
cards (Stöver et. al., 2014). SSP staff, with assistance from the harm reduction advisory council,
will research vendors to purchase preferred supplies and develop information sheets on how to
correctly use the supplies.
Due to funding and supply constraints, the SSP has been forced to limit the number of
syringes participants can receive, as well as the number of naloxone kits. Since opening in July
2018, we’ve seen a 555% increase in the number of syringes distributed and a 387% increase in
the number of encounters. In the past, we did not limit the number of syringes we gave
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participants. However, as the program grew, our supply was not able to keep up with the
demand. We were forced to limit the number of syringes participants receive. Between October
11, 2021 and January 6, 2022, we surveyed participants regarding the number of syringes they
would like to receive. Of the 478 responses, 50% reported wanting 50 syringes or less, and 50%
reported wanting more than 50 syringes per encounter. This shows we are not meeting the needs
of half of our clients, since we only give out 50 syringes if someone is not returning any
syringes. With increased funding allocated to purchasing syringes, we will reinstitute best
practice which calls for unlimited supply of syringes per encounter. Research shows programs
with no syringe restrictions are more effective at reducing the number of reuse and encouraging
clients to give sterile syringes to individuals who do not access the exchange (PEW, 2021).
In addition to funding a sufficient supply of syringes for participants, funding will also go
toward purchasing naloxone and fentanyl testing strips. Currently, our program relies primarily
on donations from harm reduction agencies to supply naloxone. Through this grant, staff will
work to secure a vendor to ensure a consistent supply of low-cost naloxone. Funding will be
allocated to purchase naloxone and fentanyl testing strips, both of which are vitally important to
combat the ongoing opioid overdose epidemic largely fueled by the fentanyl-contaminated drug
supply in North America. Along with the distribution of these materials, staff will deliver
overdose prevention education.
Clinic 555 has a long history of successful compliance with grant
requirements as exemplified in continued Title X grant funding for over fifty years. This project
will have a designated planner and program coordinator to create policy to facilitate smooth
project implementation, grounded in evidence-based trauma-informed practices. These
individuals will ensure all required grant elements, including data and evaluation, are met within
expected deadlines. This project will be guided by a harm reduction advisory council, which will
be established within four months of notice of award. The planner and program coordinator will
be responsible for creating an organization-wide strategic action plan, investigating the barriers,
strengths, and opportunities associated with this project, as well as a sustainability plan to
address program continuation. Ramsey County is committed to acting on harm reduction and
will receive opioid settlement funding beginning August 2022 that will last eighteen years.
SECTION D: Staff and Organizational Experience
D-1
Ramsey County is made up of several departments organized into service teams that offer
a variety of programs and services to thousands of people each year. It has a budget of
$772,845,689 with 4,271 FTE staff. As part of that, the Health and Wellness Service Team
(HWST) is composed of six departments, each headed by a director who reports to the Health
and Wellness Deputy County Manager. It is Ramsey County's largest Service Team in terms of
budget and number of staff and includes the following departments: Health and Wellness
Administration, Community Corrections, Financial Assistance Services, St. Paul – Ramsey
County Public Health (SPRCPH), Social Services, Veterans and Volunteer Services.
SPRCPH has 337 FTE staff with an annual operating budget of $66,398,822 and provides
a range of services as it works to protect and improve the health of people and the environment
in Ramsey County. Through federal and state mandates, the department works with community
partners to: prevent the spread of disease; protect against environmental hazards; prevent
injuries; promote and encourage healthy behaviors; plan and respond to health emergencies and
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ensure the quality and accessibility of health services. These essential services are provided by
eight divisions: Administration, Environmental Health, Family Health, Healthy Communities,
Health Protection, WIC, Clinical Services and Correctional Health. All divisions organize
community resources collaboratively with community to address local health concerns. For over
15 years, SPRCPH has provided medical services to incarcerated individuals and juveniles
in three separate Ramsey County facilities: Adult Detention Center, Juvenile Detention Center,
and the Ramsey County Correctional Facility.
SPRCPH is the largest local public health department in the state and traces its origins to
the appointment of the first public health officer by the city of St. Paul in 1854. St. Paul and
Ramsey County’s previously separate public health departments merged in 1997 through a joint
power’s agreement. The department became nationally accredited by the Public Health
Accreditation Board in 2015. Public health services and activities are characterized by a social
justice perspective that argues public health problems are primarily socially generated and can be
predicted based on the level of injustice and inequality in our society.
Ramsey County recruits, promotes, and supports a culturally and linguistically diverse
governance, leadership, and workforce that is responsive to the population in the service area and
through our community partnerships. All county departments strive to create community by
hiring individuals who look like the communities they serve. The county understands hiring is
not enough and is dedicated to building capacity for staff to provide services, while assessing
progress in their cultural educational journey. Ramsey County leads with a racial equity lens and
has demonstrated commitment through the hiring of three Racial and Health Equity
Administrators (RHEAs) for each service team, and ten Racial Equity Liaisons that work in
departments assisting the HWST RHEA and department directors with the coordination,
implementation and accountability of the department-level racial and health equity work,
priorities, and action teams. SPRCPH’s Racial and Health Equity Leadership Team (R-HELT)
has been meeting for several years, becoming a model for other county departments. Their role is
to deconstruct structures which create and deepen racial and ethnic based disparities and
reconstruct based on community needs and participation.
D-2
Saint Paul Ramsey County Public Health’s (SPRCPH) Clinic 555 opened a fixed-site
syringe service program (SSP) in July 2018. This is centrally located in downtown St. Paul
and is accessible to communities disproportionately impacted by substance use disorder
including low-income individuals, racially and ethnically diverse communities, and people
experiencing homelessness. It is the only SSP in St. Paul, and functions primarily as a safe place
to dispose of contaminated syringes and receive sterile syringes. Its wraparound services include
naloxone kit distribution and overdose prevention education; HIV, HCV, and STD testing and
linkage to care; wound care; vaccinations; and referrals to substance use disorder treatment,
medical care, mental health, and social services. The SSP is located across the hall from Clinic
555, which is a Title X-funded sexual and reproductive health clinic. SSP staff collaborate
closely with clinic staff to offer holistic services to clients, including HCV treatment and PrEP.
All encounters funded through this grant will have access to these existing services.
A Clinic 555 public health nurse, who works in the SSP, visits Ramsey County
correctional facilities three times a week to provide family planning services. The nurse provides
harm reduction education and refers all clients who report substance use for themselves or a
partner to the SSP. Staff are currently working to strengthen relationships with correctional and
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detox facilities to increase SSP referrals and naloxone training and distribution. In 2019,
SPRCPH, in collaboration with the Ramsey County Social Services and Community Corrections
Departments, implemented culturally responsive Medicated Assisted Treatment (MAT) for its
African American and Native American residents with opioid use disorder. Individuals are
assessed upon intake at correctional facilities, and if identified, see a provider for induction into
the MAT program. Once patients are released, they are connected to community-based, culturally
responsive agencies for follow-up care. For example, the Wolves Den provides culturally
specific programming for Native Americans. Referral relationships exist to allow SSP clients to
access treatment at these agencies. In 2022, Clinic 555 plans to initiate same-day-start
buprenorphine treatment for SSP clients. SSP clients will then be referred to community-based
agencies for follow-up care.
Since opening in July 2018 through 2021, the SSP distributed 885,189 sterile syringes,
passed out 14,653 naloxone kits, and collected 304,439 used syringes in 14,120 visits. The SSP
has served over 4,000 unique clients. Staff have extensive experience facilitating nonjudgmental
encounters when meeting with clients, whether during a quick exchange, when providing
confidential HIV testing, or while simply listening to someone’s story. Between August
19, 2021 and October 8, 2021, 303 clients were asked what they most liked about the syringe
exchange. The most common response (102 responses) was that staff were nice, respectful,
knowledgeable, or nonjudgmental. The second most common response (96 responses) was that
the SSP was convenient, safe, or easy to access. Since opening, staff have formed relationships
with community partners serving the same population. Staff coordinate with shelters, drop-in
centers, and supportive housing to offer syringe exchange and HIV, HCV, and STD testing at
outreach locations, as well as naloxone training for agency staff. Staff also work with
homelessness outreach workers to provide the same services at encampments. This work has
been vitally important to address the ongoing HIV epidemic primarily concentrated among
individuals who inject drugs and/or have lived in encampments in St. Paul and Minneapolis. This
proposed initiative will not have additional partner organizations.
D-3
The project director, Lisa Behr, has experience in QI/QA and evaluation and has been
successfully responsible for this area of grant management for the past six years.
The project director will have the overall responsibility of approving policies and overseeing
grant management for this project. The planner, Jessie Saavedra, has over thirty years
of on-the-ground harm reduction experience and is Ramsey County's newly appointed interim
Opioid Prevention Coordinator. The program coordinator and peer specialist will be hired for this
project. Ramsey County strives to address race and health inequities that exist due to social and
political determinants and hires staff who are familiar with the culture and population we
serve. Ramsey County applies a racial equity lens to all the work that we do in the community,
including its hiring policies. The program coordinator will direct program implementation, train
staff, manage purchases, complete quarterly reporting, and co-facilitate the harm reduction
advisory committee. The program coordinator and planner will lead data monitoring and
evaluation of process and outcome data, including how well we are reaching the target
population, and work with the team to adjust activities to reach set outcomes. The program
coordinator and planner will create the strategic action plan and sustainability
plan. The peer specialist will support program implementation through updating referral
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resources, co-facilitating the harm reduction advisory committee, and staffing fixed site and
mobile syringe exchange.
SECTION E: Data Collection and Performance Measurement
E-1
The fixed site SSP currently tracks encounter data using a software program. Staff assign
SSP clients a unique anonymous identifier, comprised of the first letter of their mom’s first name,
the first letter of their first name, and their date of birth. Upon entering the identifier into the
software, staff report current data requirements per encounter. This software is easily modified to
add additional data elements. Under this grant, staff will be required to collect race for each
client to allow data analysis on this variable. Additionally, a referral and linkage field will be
added to the software, allowing staff to determine if referrals need follow-up reporting to
determine successful linkages. Any medical services clients receive are documented in Clinic
555’s electronic health record, NextGen. NextGen is a secure electronic health record system that
meets all laws pertaining to the storage of health protected information including the Health
Insurance Portability and Accountability Act (HIPAA). All staff receive training on HIPAA
annually and are assigned tiered security when granted access to Ramsey County software.
Clinic 555 has extensive experience and expertise in public health program evaluation as a part
of the SPRCPH, one of the largest local public health departments in Minnesota and accredited
by the Public Health Accreditation Board since 2015. Through SPRCPH, Clinic 555 has access
to planners and analysts that produce the community health assessment (CHA) which analyzes
over 100 indicators of health and well-being in Ramsey County. Results of the CHA are
integrated into program planning and evaluation efforts through the Performance Improvement
Leadership Team (PILT). PILT’s purpose is to create and sustain a dynamic infrastructure that
drives organizational performance, ensures intentional and data-driven decision making, and
builds a culture of accountability, inclusiveness, and improvement. Additionally, Clinic 555 has
developed expertise in program evaluation as a recipient of Title X funding for over 50 years.
Title X is a federal grant program dedicated to providing family planning and preventive health
services using evidence-based models. Title X requires ongoing program evaluation and quality
improvement/quality assurance (QI/QA). During the last program audit in May 2021, Clinic 555
received an “Exceptional” rating in program evaluation and QI.
The project director, Lisa Behr, will have the overall responsibility of overseeing grant
management for this project. Lisa has experience in QI/QA and evaluation and has been
successfully responsible for this area of grant management for the past six years. The program
coordinator and planner will lead data monitoring and evaluation. The number of anticipated
encounters, referrals, and linkages outlined in section C are the indicators upon which project
success is evaluated. They will compile this data monthly and analyze race demographics to
ensure the target population makes up more than 50% of clients served. The program coordinator
will document all purchases made through this project on an excel sheet, which will be cross
checked regularly with the department’s requisition and ordering software. The program
coordinator is responsible for entering required variables into SAMSHA’s Performance
Accountability and Reporting System (SPARS) quarterly. Quarterly progress reports will include
project successes, challenges, and action steps to address stated challenges.
Internally, a quarterly grant review committee, consisting of the project director, planner,
project coordinator, and peer specialist, will meet to assure movement towards objectives and

106
goals are on track. Monthly reports will assess accuracy of data collection, identify possible
quality improvement opportunities, and aid in determining trends and future projections.
Strategies that are not producing desired outcomes will be revised using the Plan, Do, Study, Act
(PDSA) model. Additional tools may be used as advised by PILT. The program coordinator will
share progress with the harm reduction advisory council biannually to seek feedback regarding
improvements to goals based on the needs of the target population being served.
For detailed references, see the bottom of Attachment 10.
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APPENDIX E
Clinic 555 Attachment 10 and Reference Page - Completed SAMHSA Harm Reduction
Grant Application
Attachment 10 – Population of Focus
The Syringe Services Program (SSP) is a program through Clinic 555. Clinic 555 has
experience providing culturally relevant services in racial and ethnic communities. In 2020, 68%
of Clinic 555 clients were people of color, with 45% identifying as Black according to Family
Planning Annual Report (FPAR) data. When looking at the number of HIV tests done through
the existing SSP, it is clear most clients served belong to a racial and/or ethnic minority
community. In 2020, the SSP performed 371 HIV tests. 63% of tests were among people of
color, with 49% of tests among Native Americans. In 2021, of the 377 HIV tests completed, 51%
of tests were among people of color, with 38% of tests among Native
Americans. While some SSP client data by race is uncollected or unknown, SSP staff is
confident the current population of individuals served is more than 50% racial and/or ethnic
minority communities. Through the initiation of a mobile syringe exchange with a delivery zone
comprised of only St. Paul zip codes scoring the highest in diversity (see Figure 1 map below),
the program will continue to address the significant racial disparities relating to drug overdose
mortality especially among Blacks and Native Americans.
Priority Populations
Rural
LGBTQ
Racial and/or ethnic minority

Percent Population Served
NA- Ramsey County is urban
NA - Data not collected
60%

One of the goals of the SSP program is to help combat the significant racial disparities
within the target population by increasing the number of racially and ethnically diverse clients
with the proposed mobile SSP. The Minnesota Department of Health (MDH) has shown that
while the state has one of the lowest rates of drug overdose mortality in the United States, the
racial disparity of fatalities from overdose is one of the worst in the nation. According to the
MDH, as of 2019, Native Americans are seven times as likely to die from a drug overdose
as Whites, and Blacks are twice as likely to die compared to their white counterparts. This data
represented the largest race disparity in the nation for Native Americans and the second greatest
disparity for Blacks when compared to other states' rates of racial disparity in 2018 (Minnesota
Department of Health, 2019).
Data from national Mobile Health Clinics (MHCs) show that they serve a statistically
higher proportion of racial and ethnic minorities compared to traditional fixed-structured
facilities (Bennet et al., 2020). A national analysis of MHCs conducted in 2020 by Bennet et al.
found that while 13.4% of the general population identified as Black according to the 2010 U.S.
Census, the average percentage of clients identifying as Black utilizing MHCs was 35%. In
addition, while only 18.3% of the 2010 U.S. census respondents identified as Hispanic, data in
this study found that the average percentage of clients utilizing MHCs who identified as Hispanic
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or Latino was 26.6% (Bennet et al., 2020). Using data surrounding the population of St. Paul
from the Department of Planning and Economic Development (2021), population density maps
as seen in Figure 1 are representative of how a mobile SSP can target and access higher
proportions of POC relative to the fixed site.
Many census blocks in St. Paul show high proportions of racial diversity - see Figure 1 map
below. For example, Census Tract 336 represents 71.4% Black, 18.1% Asian, 1.9% Hispanic and
4.9% White. Census Tract 317.02 represents 27.9% Black, 24.4% Asian, 19.2% Hispanic, 2.3%
Native American and 19.8% White (U.S. Census). Using population data from the 2020 Census,
it is apparent that this proposed mobile SSP service will drastically increase access and service to
areas of higher ethnic and racial minorities.
Figure 1
Racial/Ethnic Composition by Census tract - Saint Paul, Minnesota 2020
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